documents incorporated reference document part proxy statement annual meeting shareholders held may part iii filed securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health alliances healthcare services segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products company incorporated new jersey financial information information companys segments see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales sales companys top pharmaceutical products well total sales animal health products follows millions total sales pharmaceutical januvia zetia janumet gardasilgardasil remicade isentress proquadmmr iivarivax vytorin cubicin singulair animal health consumer care revenues october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities thirdparty manufacturing sales table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders certain products within companys franchises follows primary care womens health cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states cholesterol modifying medicines diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes general medicine womens health nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma follistim aq follitropin beta injection marketed puregon countries outside united states fertility treatment hospital specialty hepatitis zepatier elbasvir grazoprevir approved us food drug administration fda january treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection without ribavirin pegintron peginterferon alphab victrelis boceprevir medicines treatment chronic hcv hiv isentress raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection hospital acute care cubicin daptomycin injection iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms cancidas caspofungin acetate antifungal product invanz ertapenem sodium treatment certain infections noxafil posaconazole prevention invasive fungal infections bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery primaxin imipenem cilastatin sodium antibacterial product immunology remicade infliximab treatment inflammatory diseases simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases company markets europe russia turkey oncology keytruda pembrolizumab treatment advanced melanoma metastatic nonsmallcell lung cancer nsclc patients whose tumors express pdl disease progression following therapies emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting temodar temozolomide marketed temodal outside united states treatment certain types brain tumors diversified brands respiratory singulair montelukast medicine indicated chronic treatment asthma relief symptoms allergic rhinitis nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms clarinex desloratadine nonsedating antihistamine cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company markets outside united states fosamax alendronate sodium marketed fosamac japan treatment prevention osteoporosis zocor simvastatin statin modifying cholesterol propecia finasteride product treatment male pattern hair loss table contents vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpes zoster rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorders cattle matrix fertility management swine resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiencies beef cattle safeguard dewormer cattle mpac swine pneumonia vaccine porcilis circumvent vaccine lines infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products bravecto chewable tablet kills fleas ticks dogs weeks nobivac vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals regumate fertility management horses prestige vaccine line horses activylscaliborexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish discussion sales companys products see item managements discussion analysis financial condition results operations product approvals january merck announced fda approved zepatier treatment adult patients chronic hcv gt gt infection without ribavirin december merck announced fda approved expanded age indication gardasil mercks valent hpv vaccine include use males years age prevention anal cancers precancerous dysplastic lesions genital warts caused certain hpv types gardasil includes greatest number hpv types available hpv vaccine also december company announced fda approved expanded indication keytruda antipd programmed death receptor therapy include firstline treatment patients unresectable metastatic melanoma additionally fda approved update product labeling keytruda treatment patients ipilimumabrefractory advanced melanoma october fda granted accelerated approval keytruda dose mgkg every three weeks treatment patients metastatic nsclc whose tumors express pdl determined fdaapproved test disease progression platinumcontaining chemotherapy patients egfr alk genomic tumor aberrations disease progression fdaapproved therapy aberrations prior receiving keytruda addition approving keytruda nsclc fda approved first companion diagnostic enable physicians determine level pdl expression patients tumor table contents september merck announced japanese pharmaceuticals medical devices agency approved marizev omarigliptin mg mg tablets oral onceweekly dipeptidyl peptidase dpp inhibitor indicated treatment adults type diabetes japan first country approved omarigliptin joint ventures sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution thenexisting european union eu european free trade association merck sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc spmsd joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom uk distributors rest territory licenses subsidiary scheringplough corporation scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system european commission ec approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi eu following receipt pricing reimbursement approval within eu remicade lost market exclusivity major european markets february company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements refining sales marketing efforts address table contents changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation patient protection affordable care act began implemented various insurance market reforms advanced state federal insurance exchanges launched end decade law expected expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee higher expenses reflect final regulations annual health care reform fee issued internal revenue service irs july final irs regulations accelerated recognition criteria fee obligation one year year underlying sales used allocate fee occurred rather year fee paid result change merck recorded additional year expense million january centers medicare medicaid services issued medicaid rebate final rule implements provisions patient protection affordable care act effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs merck still evaluating rule determine whether material impact mercks medicaid rebate liability company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation table contents medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company efforts toward health care cost containment remain intense several european countries many countries continued announce execute austerity measures include implementation pricing actions reduce prices generic patented drugs mandatory switches generic drugs company taking steps mitigate impact countries austerity measures continued negatively affect companys revenue performance company anticipates austerity measures continue negatively affect revenue performance addition majority countries attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occur furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement companys focus emerging markets increased governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation appears accelerated regulatory review process medicines designation table contents eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck launched merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent organization partnered variety organizations dedicated improving global health privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability efficiently transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including new eu general data protection regulation become effective impose penalties four percent global revenue additional laws regulations enacted united states europe asia latin america increased enforcement litigation activity united states developed markets increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks certified compliant asia pacific economic cooperation crossborder privacy rules system regulatory review eu october court justice eu invalidated decision ec held useu safe harbor framework safe harbor provided adequate protection transfers personal data european economic area united states merck annually selfcertified adherence safe harbor since relied safe harbor significant number data transfers across business since november merck working toward regulatory recognition global privacy program meeting eus binding corporate rules requirements alternative legal mechanism internal company transfers end january eu review companys binding corporate rules application completed eu member states participate eu mutual recognition process completion final eu cooperation review phase expected first quarter binding corporate rules approval eu expected reduce operational impact safe harbor invalidation global business crossborder data transfers third parties support companys business directly facilitated binding corporate rules approved however company anticipates standards global privacy program met binding corporate rules review support ability comply new euus privacy shield transatlantic data transfer agreement replace safe harbor announced february well continue implement data transfer mechanisms necessary support business table contents distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda table contents patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including potential patent term restoration pediatric exclusivity indicated following marketed products product year expiration us invanz compound composition cubicin composition zostavax use dulera formulation combination zetiavytorin asmanex formulation nasonex formulation nuvaring delivery system emend injection noxafil rotateq intron recombivax method makingvectors januviajanumetjanumet xr isentress bridion pending patent term restoration nexplanon device device applicator grastek use ragwitek use bravecto pending patent term restoration zontivity pending patent term restoration gardasilgardasil keytruda zerbaxa pending patent term restoration sivextro pending patent term restoration belsomra zepatier compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities december decision district court action hospira inc hospira june patent found valid infringed later patents cubicin expiring september november found invalid november us court appeals federal circuit cafc affirmed lower court decision hospiras application fda approved least june earlier district court action teva resulted settlement whereby teva launch generic version cubicin latest december earlier certain conditions event june agreement generic manufacturer may launch generic version zetia united states december district court decision upheld appeal cafc found proposed generic product apotex generic manufacturer would infringe mercks nasonex formulation patent thus apotexs application approved fda enter market united states generic version nasonex eligible months pediatric exclusivity expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset table contents increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review united states fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review year expiration us v pediatric hexavalent combination vaccine method makingvectors mk bezlotoxumab company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us v inactivated varicella zoster virus vzv vaccine use v ebola vaccine mk odanacatib mk letermovir mk allergy house dust mites use mk anacetrapib mka relebactam imipenemcilastatin mk omarigliptin mk verubecestat mk ertugliflozin mka ertugliflozin sitagliptin mkb ertugliflozin metformin mk doravirine mkb contraception next generation ring unless otherwise noted patents charts compound patents patent subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion table contents billion included restructuring costs acquisition divestiturerelated costs years company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed making externally sourced programs greater component pipeline strategy renewed focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases neurodegenerative diseases osteoporosis respiratory diseases womens health development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologics molecule believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory table contents filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review addition generating antibiotic incentives act fda may grant qualified infectious disease product qidp status antibacterial antifungal drugs intended treat serious life threatening infections including caused antibiotic antifungal resistant pathogens novel emerging infectious pathogens qualifying pathogens qidp designation offers certain incentives development qualifying drugs including priority review nda filed eligibility fast track designation fiveyear extension applicable exclusivity provisions food drug cosmetic act primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples pharmaceuticals medical devices agency japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline many markets approval times longer regulatory authority requires approval table contents major market united states eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review united states internationally keytruda fdaapproved antipd therapy clinical development expanded indications different cancer types keytruda currently approved treatment melanoma advanced melanoma nsclc december merck announced results pivotal keynote study evaluate potential immunotherapy compared chemotherapy based prospective measurement pdl expression patients advanced nsclc phase study keytruda significantly improved overall survival compared chemotherapy patients level pdl expression based data merck submitted supplemental bla fda filed maa ema november merck announced fda granted breakthrough therapy designation keytruda treatment patients microsatellite instability high metastatic colorectal cancer keytruda previously granted breakthrough therapy status advanced melanoma advanced nsclc keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck melanoma multiple myeloma non smallcell lung triple negative breast several currently phase clinical development mk bezlotoxumab investigational antitoxin prevention clostridium difficile c difficile infection recurrence currently review fda ema january merck announced fda accepted review bla bezlotoxumab granted priority review pdufa action date july september merck announced two pivotal phase clinical studies bezlotoxumab met primary efficacy endpoint reduction c difficile recurrence week compared placebo used conjunction standard care antibiotics treatment c difficile company also seeking approval eu intends file canada currently therapies approved prevention recurrent disease caused c difficile mk insulin glargine candidate treatment patients type type diabetes developed collaboration samsung bioepis december company submitted application regulatory approval eu plans submit mk fda mka zepatier currently review eu treatment chronic hcv oncedaily fixeddose combination tablet containing nsa inhibitor elbasvir mg nsa protease inhibitor grazoprevir mg zepatier approved fda january treatment adult patients chronic hcv gt gt infection without ribavirin v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized partnership merck sanofi pasteur vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b november fda issued crl respect bla v companies reviewing crl plan communication fda february ec granted marketing authorization v prophylaxis diphtheria tetanus pertussis hepatitis b poliomyelitis invasive disease caused hib infants toddlers age weeks v marketed vaxelis eu spmsd companys joint venture sanofi pasteur addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed company anticipates filing applications regulatory approval fda respect certain candidates including mk noted mk odanacatib oral onceweekly investigational treatment patients osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures table contents odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis september merck announced data pivotal phase fracture outcomes study odanacatib postmenopausal women osteoporosis longterm odanacatib fracture trial loft odanacatib met primary endpoints significantly reduced risk three types osteoporotic fractures radiographicallyassessed vertebral clinical hip clinical nonvertebral compared placebo also reduced risk secondary endpoint clinical vertebral fractures addition treatment odanacatib led progressive increases five years bone mineral density lumbar spine total hip rates adverse events overall loft generally balanced patients taking odanacatib placebo adjudicated events morphea like skin lesions atypical femoral fractures occurred often odanacatib group placebo group adjudicated major adverse cardiovascular events generally balanced overall treatment groups numerically adjudicated stroke events odanacatib placebo adjudicated atrial fibrillation reported often odanacatib group placebo group numeric imbalance mortality observed numeric difference appear related particular reported cause causes death merck continues collect data blinded extension study planning additional analyses data trial including independent readjudication major adverse cardiovascular events mace support regulatory submissions merck plans submit nda fda odanacatib following completion independent adjudication analysis mace merck also plans submit applications ema ministry health labour welfare japan mk omarigliptin investigational onceweekly dpp inhibitor development treatment adults type diabetes september company announced omarigliptin achieved primary efficacy endpoint phase study omarigliptin found noninferior januvia reducing patients ac estimate persons blood glucose twoto threemonth period levels baseline similar ac reductions achieved groups headtohead study designed evaluate onceweekly treatment omarigliptin mg compared mg januvia daily results presented oral session st european association study diabetes annual meeting also september merck announced japanese pharmaceuticals medical devices agency approved marizev omarigliptin mg mg tablets japan first country approved omarigliptin merck plans submit omarigliptin regulatory approval united states worldwide regulatory submissions follow mk ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes collaboration pfizer inc ertugliflozin also studied combination januvia sitagliptin metformin merck expects submit applications regulatory approval united states ertugliflozin two fixeddose combination tablets end mk investigational allergy immunotherapy tablet house dust mite allergy part north america partnership merck alkabello merck plans submit nda fda mk first half mk verubecestat mercks novel investigational oral amyloid precursor protein sitecleaving enzyme bace inhibitor treatment alzheimers disease studied phase trial apecs designed evaluate safety efficacy mk versus placebo patients amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease mk also studied another phase randomized placebocontrolled study patients mildtomoderate alzheimers disease epoch epoch study completed enrollment fourth quarter estimated reach primary trial completion mid mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raising hdlc reducing ldl c anacetrapib evaluated patient eventdriven cardiovascular clinical outcomes trial sponsored oxford university reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease projected conclude early november merck announced data monitoring committee dmc reveal outcomes study completed planned review unblinded study data recommended study continue changes dmc reviewed safety efficacy data study included assessment futility merck remains blinded actual results analysis reveal safety efficacy data table contents reveal steering committee merck continue monitor progress study additional interim efficacy analyses planned mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qidp designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections mk letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir received orphan drug status eu united states also granted fast track designation mkb referred next generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea women seeking contraception mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor codeveloped astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials currently underway west africa november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola procedure intended assist united nations procurement agencies member states acceptability using vaccine candidate emergencyuse setting eual designation prequalification rather special procedure implemented outbreak disease high rates morbidity andor mortality lack treatment andor prevention options instances may recommend making vaccine available limited time clinical trial data gathered formal regulatory agency review national regulatory authority decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution v inactivated varicella zoster virus vzv vaccine development prevention herpes zoster company conducting two phase trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies mk doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor developed merck treatment hiv infection company also divested discontinued certain drug candidates july merck allergan plc allergan entered agreement pursuant allergan acquired exclusive worldwide rights mk mk mercks investigational small molecule oral calcitonin generelated peptide receptor antagonists developed treatment prevention migraine mk surotomycin investigational oral antibiotic development treatment c difficile associated diarrhea merck acquired surotomycin part purchase cubist second quarter company received unfavorable efficacy data randomized doubleblinded activecontrolled study patients c difficile associated diarrhea evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program mk bevenopran oral investigational therapy development potential treatment opioidinduced constipation patients chronic noncancer pain merck acquired bevenopran part purchase cubist company made decision continue development program seeking outlicense asset table contents mk corifollitropin alfa injection investigational fertility treatment controlled ovarian stimulation women participating assisted reproductive technology july merck received crl fda nda corifollitropin alfa injection merck made decision discontinue development corifollitropin alfa injection united states business reasons corifollitropin alfa injection marketed elonva certain markets outside united states chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area additional claims line extensions formulations inline products shown phase phase phase entry date review alzheimers disease allergy cancer mk mk house dust mite march mk keytruda asthma alzheimers disease nonsmallcell lung eu mk mk verubecestat december clostridium difficile infection cancer atherosclerosis mk bezlotoxumab useu mk keytruda mk anacetrapib may diabetes mellitus hodgkin lymphoma bacterial infection mk eu pmbcl primary mediastinal mka relebactamimipenemcilastatin hepatitis c large bcell lymphoma october mka zepatier eu advanced solid tumors cancer pediatric hexavalent combination vaccine mk mk keytruda v us mk bladder october diabetes breast october footnotes mk colorectal november heart failure esophageal december developed collaboration mk vericiguat gastric may north american rights hepatitis c head neck november v investigational pediatric hexavalent combination vaccine dtap mkb mkmk multiple myeloma december ipvhibhepb developed approved mk grazoprevir cmv prophylaxis transplant patients commercialized partnership merck sanofi pasteur pneumoconjugate vaccine mk letermovir june november fda issued crl respect v v contraception next generation ring companies reviewing crl plan communication mkb september fda diabetes mellitus mk omarigliptin september mk ertugliflozin november mka ertugliflozinsitagliptin september mkb ertugliflozinmetformin august mk february us mkj sitagliptinipragliflozin october japan ebola vaccine v march herpes zoster v inactivated vzv vaccine december hiv mk doravirine december osteoporosis mk odanacatib september employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups restructuring program company initiated actions global restructuring program restructuring program part global initiative sharpen commercial research development focus actions table contents program primarily include elimination positions sales administrative headquarters organizations well research development additionally actions include reduction companys global real estate footprint improvements efficiency manufacturing supply network since inception restructuring program december merck eliminated approximately positions comprised employee separations well elimination contractors vacant positions actions restructuring program substantially completed end merger restructuring program subsequent merck scheringplough merger merger company commenced actions global restructuring program merger restructuring program designed streamline cost structure combined company actions program initiated actions program primarily include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities since inception merger restructuring program december merck eliminated approximately positions comprised employee separations well elimination contractors vacant positions nonfacility related restructuring actions merger restructuring program substantially completed environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck expanded operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business provided item financial statements supplementary data table contents available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation relating patents well regulatory initiatives may result erosion intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain products loss could result material noncash impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products table contents chart listing us patent protection certain companys marketed products candidates review phase candidates set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects example court ruled proposed generic form nasonex infringe companys us patent nasonex generic form nasonex receives marketing approval united states company experience loss nasonex sales addition company lose us patent protection cubicin june also pursuant agreement generic manufacturer manufacturer may launch united states generic version zetia december key company products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products januvia zetia janumet gardasilgardasil isentress vytorin result companys dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postmarket trials increased competition introduction new effective treatments discontinuation removal market product reason events material adverse effect sales certain products event could result material noncash impairment charge companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing table contents company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval table contents developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postmarketing phase trials studies may decrease demand companys products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lower costgeneric products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead noncash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective table contents convenient use effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products company faces pricing pressure respect products company faces increasing pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures company also faces risk litigation government pricing calculations addition us larger customers may future ask receive higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization outside united states numerous major markets including eu japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered congress state legislatures united states enacted major health care reform legislation patient protection affordable care act various insurance market reforms advanced state federal insurance exchanges launched end decade law expected expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid january centers medicare medicaid services issued medicaid rebate final rule implements provisions patient protection affordable care act effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs merck still evaluating rule determine whether material impact mercks medicaid rebate liability table contents company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business uncertainty global economic conditions together austerity measures taken certain governments could negatively affect companys operating results uncertainty global economic conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects global efforts toward health care cost containment continue exert pressure product pricing market access many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan occur austerity measures continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease past company experienced difficulties delays manufacturing certain products previously disclosed merck past experienced difficulties manufacturing certain vaccines products company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales reputational harm company table contents company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected addition china commercial economic conditions may adversely affect companys growth prospects market company continues believe china represents important growth opportunity events coupled heightened scrutiny health care industry may continue impact product pricing market access generally company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however failure continue expand companys business emerging markets could material adverse effect business financial condition results companys operations company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows occurred respect venezuela order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued march president obamas administration reproposed significant changes us international tax laws including changes would tax companies excess returns attributable certain offshore intangible assets limit us tax deductions expenses related unrepatriated foreignsource income modify us foreign tax credit rules potentially significant changes us international laws including move toward territorial tax system taxing currently accumulated unrepatriated foreign earnings controlled foreign corporations set various congressional committees company determine whether proposals enacted law changes may made proposals prior enacted law changes us international tax laws enacted could significant impact financial results company table contents addition company may affected changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure companys workforce others authorized access companys systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored companys systems nonencrypted portable media storage devices company could also experience business interruption intentional theft confidential information reputational damage espionage attacks malware cyberattacks insider threat attacks may compromise companys system infrastructure lead data leakage either internally companys thirdparty providers although aggregate impact companys operations financial condition material date company target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems prevent service interruption loss critical sensitive information companys companys third party providers databases systems could result financial legal business reputational harm company negative events animal health industry could negative impact future results operations future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant table contents biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval required release manufactured commercial lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living micro organisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business table contents social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company social networking web site could damage companys reputation brand image goodwill disclosure nonpublic company sensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand presents new challenges cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products table contents lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located kenilworth new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd cokesbury new jersey companys vaccines business conducted divisional headquarters located west point pennsylvania mercks animal health global headquarters function located madison new jersey principal us research facilities located rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facilities outside united states located switzerland china mercks manufacturing operations headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia capital expenditures billion billion billion united states amounted million million million abroad expenditures amounted million million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february kenneth c frazier age december chairman president chief executive officer january president chief executive officer may president responsible companys three largest global divisions global human health merck manufacturing division merck research laboratories prior may mr frazier executive vice president president global human health adele ambrose age november senior vice president chief communications officer responsible global communications organization robert davis age april executive vice president chief financial officer responsible companys global financial organization investor relations corporate strategy business development global facilities companys joint venture relationships prior april mr davis corporate vice president president medical products baxter international inc baxter corporate vice president president renal division baxter baxters corporate vice president chief financial officer willie deese age november executive vice president president merck manufacturing division responsible companys global manufacturing procurement distribution logistics functions richard r deluca jr age september executive vice president president merck animal health responsible merck animal health organization prior september mr deluca chief financial officer becton dickinson biosciences medical technology company since president wyeths fort dodge animal health division julie l gerberding md mph age january executive vice president strategic communications global public policy population health responsible mercks global public policy corporate responsibility global communications functions january president merck vaccines responsible mercks portfolio vaccines planning introduction vaccines companys pipeline accelerating efforts broaden access mercks vaccines around world table contents clark golestani age december executive vice president chief information officer responsible companys global information technology organization august vice president merck research laboratories information technology responsible global companys research development division including basic research preclinical clinical regulatory mirian graddickweir age november executive vice president human resources responsible global human resources organization michael j holston age july executive vice president general counsel responsible companys legal function june executive vice president chief ethics compliance officer responsible companys global compliance function including global safety environment systems assurance ethics privacy security organization prior june mr holston executive vice president general counsel board secretary hewlettpackard company since oversaw legal compliance government affairs privacy ethics operations rita karachun age march senior vice president finance global controller responsible companys global controllers organization including accounting controls external reporting financial standards policies november assistant controller responsible global consolidation companys entities well acting controller us based entities roger perlmutter md phd age april executive vice president president merck research laboratories responsible companys global research development efforts prior april dr perlmutter executive vice president research development amgen inc michael rosenblatt md age december executive vice president chief medical officer companys primary voice global medical community critical issues patient safety benefitrisk medications adam h schechter age may executive vice president president global human health responsible companys global pharmaceutical vaccine business november president global human health us market integration leader commercial responsibility united states companys portfolio prescription medicines leader integration efforts merckscheringplough merger across divisions functions officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low january approximately shareholders record issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors march purchase billion merck shares table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbvie inc bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis addition abbvie inc replaced abbott laboratories peer group beginning following spin abbott laboratories performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include net charge related settlement vioxx shareholder class action litigation foreign exchange losses related venezuela gains dispositions businesses assets favorable benefit certain tax items amounts reflect divestiture mercks consumer care business october including gain sale well gain recognized option exercise astrazeneca gains dispositions businesses assets loss extinguishment debt amounts include net charge recorded connection settlement certain shareholder litigation amounts include arbitration settlement charge amounts restated give effect early adoption accounting guidance issued financial accounting standards board see note item financial statements table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health alliances healthcare services segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products overview merck continued execute research development focusedstrategy advance pipeline commercial portfolio maintaining disciplined approach cost management delivering capital returns shareholders company received several product approvals include expanded indications keytruda companys antipd programmed death receptor therapy treatment advanced melanoma metastatic non smallcell lung cancer nsclc patients whose tumors express pdl disease progression following therapies well us food drug administration fda approval bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery additionally january fda approved zepatier oncedaily single tablet combination therapy treatment chronic hepatitis c virus hcv genotype gt gt infection without ribavirin business development critical part companys strategy merck looks combine internal external innovation enhance pipeline merck acquired cubist pharmaceuticals inc cubist leader development new therapies treat serious potentially lifethreatening infections caused broad range increasingly drugresistant bacteria ccam biotherapuetics ltd ccam biopharmaceutical company focused discovery development novel cancer immunotherapies also merck entered multiyear collaboration ngm biopharmaceuticals inc ngm research discover develop commercialize novel biologic therapies across wide range therapeutic areas january merck acquired iomet pharma ltd iomet drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism worldwide sales billion decline compared including unfavorable effect foreign exchange acquisition cubist divestiture mercks consumer care business mcc well product divestitures termination companys relationship astrazeneca lp azlp net unfavorable impact sales approximately sales performance also unfavorably affected ongoing impacts loss market exclusivity several products unfavorable impacts partially offset volume growth oncology diabetes womens health vaccine products positive performance mercks animal health business merck continues support inline portfolio well ongoing upcoming product launches keytruda initially approved fda september treatment advanced melanoma patients disease progression therapies launching markets including european union eu merck achieved multiple additional regulatory milestones keytruda including accelerated approval fda table contents treatment patients metastatic nsclc whose tumors express pdl determined fdaapproved test disease progression platinumcontaining chemotherapy addition fda approved expanded indication keytruda include firstline treatment patients unresectable metastatic melanoma additionally european commission ec approved keytruda treatment advanced unresectable metastatic melanoma adults keytruda clinical trials program currently includes tumor types clinical trials including trials combine keytruda cancer treatments see research development company also launching zepatier bridion united states company continues execute strategy pursuing business development opportunities complement internal research capabilities part mercks prioritization efforts company also continues review existing assets determine whether provide best short longerterm value merck elsewhere connection portfolio assessment process company divested remaining ophthalmics business international markets companys portfolio assessment process ongoing future divestitures may occur merck focusing research efforts therapeutic areas believes make impact addressing critical areas unmet medical need cancer hepatitis c cardiometabolic disease resistant microbial infection alzheimers disease company continued make strides latestage pipeline mk bezlotoxumab investigational antitoxin prevention clostridium difficile c difficile infection recurrence currently review fda european medicines agency ema mk insulin glargine candidate treatment patients type type diabetes developed collaboration also review eu zepatier keytruda review eu treatment nsclc addition phase programs keytruda therapeutic areas bladder breast colorectal gastric head neck multiple myeloma esophageal cancers company also candidates phase clinical development core therapeutic areas well areas significant potential including mk omarigliptin investigational onceweekly dipeptidyl peptidase dpp inhibitor development treatment adults type diabetes mk odanacatib oral onceweekly investigational treatment patients osteoporosis mk ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated alone combination januvia sitagliptin metformin treatment type diabetes mk investigational allergy immunotherapy tablet house dust mite allergy merck expects submit applications regulatory approval united states candidates well mk described result continued portfolio prioritization company outlicensing discontinuing selected latestage clinical development assets company outlicensed mk mk investigational small molecule oral calcitonin generelated peptide cgrp receptor antagonists developed treatment prevention migraine company continued make strong progress reducing cost base result disciplined cost management merck achieved overall savings goal noted company turn invested resources grow strongest brands support promising assets pipeline marketing administrative expenses declined compared reflecting part continued focus company prioritizing resources highest growth areas company initiated actions global restructuring program restructuring program part global initiative sharpen commercial research development focus actions program primarily include elimination positions sales administrative headquarters organizations well research development additionally actions include reduction companys global real estate footprint improvements efficiency manufacturing supply network company recorded total pretax costs million billion related restructuring program actions restructuring program substantially completed end company met projected billion annual net cost savings actions restructuring program actions restructuring program combined actions merger restructuring program discussed company also met annual net cost savings projection billion compared fullyear expense levels table contents global restructuring program merger restructuring program initiated subsequent merck scheringplough corporation scheringplough merger merger intended streamline cost structure combined company actions plan include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company recorded total pretax costs million million billion related restructuring program nonfacility related restructuring actions merger restructuring program substantially complete beginning january remaining restructuring actions plans primarily relate ongoing facility rationalizations accounted aggregate prospectively company expects complete actions end incur approximately billion additional pretax costs costs associated companys restructuring actions included materials production costs marketing administrative expenses research development expenses restructuring costs company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested november mercks board directors raised companys quarterly dividend per share per share company returned billion shareholders dividends share repurchases january merck announced reached agreement plaintiffs resolve vioxx shareholder class action litigation pending new jersey federal court agreement merck pay million resolve settlement class members claims plus additional amount approved attorneys fees expenses connection settlement merck recorded net pretax charge million fourth quarter includes anticipated insurance recoveries see note consolidated financial statements earnings per common share assuming dilution attributable common shareholders eps compared eps years reflect impact acquisition divestiturerelated costs restructuring costs well certain items include billion gain recognized connection divestiture mcc nongaap eps excludes items see nongaap income nongaap eps competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number table contents compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation patient protection affordable care act began implemented various insurance market reforms advanced state federal insurance exchanges launched end decade law expected expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee higher expenses reflect final regulations annual health care reform fee issued internal revenue service irs july final irs regulations accelerated recognition criteria fee obligation one year year underlying sales used allocate fee occurred rather year fee paid result change merck recorded additional year expense million january centers medicare medicaid services issued medicaid rebate final rule implements provisions patient protection affordable care act effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs merck still evaluating rule determine whether material impact mercks medicaid rebate liability company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company table contents efforts toward health care cost containment remain intense several european countries many countries continued announce execute austerity measures include implementation pricing actions reduce prices generic patented drugs mandatory switches generic drugs company taking steps mitigate impact countries austerity measures continued negatively affect companys revenue performance company anticipates austerity measures continue negatively affect revenue performance addition majority countries attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occur furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement companys focus emerging markets increased governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation appears accelerated regulatory review process medicines designation table contents eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment operating results sales worldwide sales billion decline compared including unfavorable effect foreign exchange acquisition cubist divestiture mcc well product divestitures termination companys relationship astrazeneca lp azlp also discussed net unfavorable impact sales approximately addition sales performance reflects declines pegintron victrelis medicines treatment hcv remicade treatment inflammatory diseases pneumovax vaccine help prevent pneumococcal disease nasonex inhaled corticosteroid treatment nasal allergy symptoms vytorin cholesterol modifying medicine declines partially offset volume growth keytruda antipd therapy januvia janumet treatment type diabetes gardasilgardasil vaccines help prevent certain diseases caused certain types human papillomavirus hpv noxafil prevention invasive fungal infections simponi oncemonthly subcutaneous treatment inflammatory diseases implanonnexplanon singlerod subdermal contraceptive implants invanz treatment certain infections dulera inhalation aerosol combination medicine treatment asthma bridion medication reversal two types neuromuscular blocking agents used surgery well volume growth animal health products higher thirdparty manufacturing sales january company acquired cubist contributed sales billion mercks revenues company divested certain ophthalmic products several international markets closed july addition october company divested mcc business including prescription rights claritin afrin sales decline attributable divestitures approximately billion billion related consumer care segment million related pharmaceutical segment also company sold us marketing rights saphris antipsychotic indicated treatment schizophrenia bipolar disorder adults resulted revenue million additionally companys relationship azlp terminated june therefore effective july company longer records supply sales azlp supply sales million termination date reflected alliances segment sales united states billion increase compared billion increase driven primarily acquisition cubist well higher sales keytruda gardasilgardasil januviajanumet zetia cholesterol modifying medicine higher thirdparty manufacturing sales increases partially offset divestiture mcc termination companys relationship azlp revenue recognized connection sale us marketing rights saphris well lower sales pneumovax nasonex international sales billion decline compared billion foreign exchange unfavorably affected international sales performance excluding unfavorable effect foreign exchange sales decrease reflects divestiture mcc well lower sales pharmaceutical segment largely reflecting declines europe japan partially offset growth emerging markets sales europe declined billion including unfavorable effect foreign exchange excluding unfavorable effect foreign exchange decline driven primarily lower sales remicade well lower sales products treatment hcv product divestitures ongoing generic erosion fiscal austerity measures region partially offset growth simponi keytruda januviajanumet sales japan declined billion due unfavorable effect foreign exchange sales decline largely driven product divestitures ongoing impacts loss market exclusivity several products including cozaar hyzaar treatments hypertension well lower sales pegintron januvia table contents sales emerging markets billion decline including unfavorable effect foreign exchange excluding unfavorable effect foreign exchange sales performance reflects volume growth diabetes hospital acute care oncology certain diversified brand products partially offset lower sales hcv products well product divestitures total international sales represented total sales respectively global efforts toward health care cost containment continue exert pressure product pricing market access worldwide united states health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan occur austerity measures continue negatively affect revenue performance worldwide sales totaled billion decline compared billion foreign exchange unfavorably affected global sales performance decline reflects lower revenue resulting ongoing impacts loss market exclusivity several products including temodar treatment certain types brain tumors singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis cozaar hyzaar addition sales decline attributable product divestitures occurred discussed termination companys relationship azlp well divestiture mcc revenue decline also driven lower sales victrelis pegintron nasonex vytorin declines partially offset growth remicade simponi diabetes franchise januviajanumet dulera inhalation aerosol implanonnexplanon well higher sales hospital acute care animal health products addition company recognized revenue million connection sale us marketing rights saphris october company sold active pharmaceutical ingredient api manufacturing business effective december certain related products within diversified brands november merck sold us rights certain ophthalmic products january sold us marketing rights saphris addition company sold us rights zioptan april also noted company divested certain ophthalmic products several international markets sold mcc business sales decline attributable divestitures approximately billion approximately million related pharmaceutical segment million related consumer care segment million related divested api manufacturing business nonsegment revenues also termination companys relationship azlp resulted sales decline approximately million alliances segment compared table contents sales companys products follows millions primary care womens health cardiovascular zetia vytorin diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon dulera follistim aq hospital specialty hepatitis pegintron hiv isentress hospital acute care cubicin cancidas invanz noxafil bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex clarinex cozaarhyzaar arcoxia fosamax zocor propecia vaccines gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales cubicin represent sales subsequent cubist acquisition date sales cubicin reflect sales japan pursuant previously existing licensing agreement amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates included income expense net amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health alliances healthcare services well consumer care divestiture october alliances segment includes revenue companys relationship azlp termination june revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales revenues also include million received merck connection sale us marketing rights saphris revenues reflect million revenue outlicense pipeline compound table contents pharmaceutical segment primary care womens health cardiovascular combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy medicines lowering ldl cholesterol billion decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes ezetrol canada lost market exclusivity september well lower volumes united states partially offset higher pricing united states combined worldwide sales zetia vytorin billion decline compared foreign exchange unfavorably affected global sales performance sales decline driven primarily lower volumes vytorin united states ezetrol canada due loss market exclusivity november merck announced investigational improveit study improved reduction outcomes vytorin efficacy international trial met primary secondary composite efficacy endpoints improveit patients taking vytorin combines simvastatin zetia experienced significantly fewer major cardiovascular events measured composite cardiovascular death nonfatal myocardial infarction nonfatal stroke hospitalization unstable angina coronary revascularization occurring least days randomization patients treated simvastatin alone results patient study highrisk patients presenting acute coronary syndromes presented american heart association scientific sessions april merck submitted data improveit fda support new indication reduction cardiovascular events vytorin zetia vytorin zetia currently indicated use along healthy diet reduce elevated ldl cholesterol patients hyperlipidemia current us prescribing information products states effect ezetimibe cardiovascular morbidity mortality alone incremental statin therapy determined february merck announced fda issued complete response letter crl regarding mercks supplemental new drug applications merck reviewing letter determine next steps also february decentralized process merck received positive outcome mutual recognition procedure updated product information ezetrol inegy based results improveit following completion procedure eu member states concerned amend local labeling country country basis include reduction risk cardiovascular events patients coronary heart disease history acute coronary syndrome agreement generic manufacturer may launch generic version zetia united states december us patent exclusivity periods zetia vytorin otherwise expire april company market exclusivity ezetrol major european markets october however company expects apply pediatric extensions term would extend date april company market exclusivity inegy markets april may merck announced fda approved zontivity reduction thrombotic cardiovascular events patients history myocardial infarction peripheral arterial disease us prescribing information zontivity includes boxed warning regarding bleeding risk january zontivity approved ec coadministration acetylsalicylic acid appropriate clopidogrel reduce atherothrombotic events adult patients history myocardial infarction merck currently plans begin launching zontivity certain european markets company continues monitor assess zontivity related intangible asset merck continues focus building product awareness united states zontivity companys efforts build product awareness united states launches europe successful company may take noncash impairment charge respect zontivity intangible asset million december diabetes worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes billion essentially flat compared including unfavorable effect foreign exchange sales performance reflects higher volumes pricing united states well volume growth emerging markets europe volume declines comarketed sitagliptin japan due timing sales licensee partially offset growth combined global sales januvia janumet billion increase compared including unfavorable effect foreign exchange table contents growth driven primarily higher sales januvia janumet united states volume growth europe partially offset lower sales januvia japan due lower pricing april dpp inhibitors including januvia subject repricing japan june merck announced primary results trial evaluating cardiovascular outcomes sitagliptin tecos placebocontrolled study cardiovascular cv safety mercks dpp inhibitor januvia sitagliptin added usual care patients study achieved primary composite cv endpoint noninferiority defined time first confirmed event following cvrelated death nonfatal myocardial infarction nonfatal stroke hospitalization unstable angina compared usual care without sitagliptin addition increase hospitalization heart failure rates allcause mortality similar treatments groups two key secondary endpoints data presented annual scientific meeting american diabetes association june september merck announced japanese pharmaceuticals medical devices agency approved marizev omarigliptin mg mg tablets oral onceweekly dpp inhibitor indicated treatment adults type diabetes japan first country approved omarigliptin worldwide regulatory submissions follow general medicine womens health worldwide sales nuvaring vaginal contraceptive product million increase compared million increase compared foreign exchange unfavorably affected global sales performance respectively sales growth years largely reflects higher pricing united states worldwide sales implanonnexplanon singlerod subdermal contraceptive implants rose million increase compared including unfavorable effect foreign exchange increase driven primarily higher demand united states emerging markets implanonnexplanon sales grew million compared driven primarily higher demand united states global sales dulera inhalation aerosol combination medicine treatment asthma grew million increased million driven primarily higher demand united states global sales follistim aq marketed countries outside united states puregon fertility treatment million decline compared reflecting unfavorable effect foreign exchange offset higher pricing united states worldwide sales follistim aq declined million compared driven largely lower pricing united states well lower sales europe driven primarily volume declines foreign exchange unfavorably affected global sales performance patent provided market exclusivity follistim aq united states expired june hospital specialty hepatitis worldwide sales pegintron treatment chronic hcv million decline compared including unfavorable effect foreign exchange decline driven lower volumes nearly regions availability newer therapeutic options continues reduce market share global sales pegintron million decline compared including unfavorable effect foreign exchange decrease driven lower volumes regions availability newer therapeutic options resulted loss market share led patient treatment delays markets anticipating availability new therapeutic options global sales victrelis oral medicine treatment chronic hcv million decline compared driven lower volumes europe emerging markets availability newer therapeutic options continues reduce market share worldwide sales victrelis million decline compared driven lower volumes nearly regions particularly within united states availability newer therapeutic options resulted loss market share led patient treatment delays markets anticipating availability newer therapeutic options table contents january fda approved zepatier treatment adult patients chronic hcv gt gt infection without ribavirin zepatier oncedaily fixeddose combination tablet containing nsa inhibitor elbasvir mg nsa protease inhibitor grazoprevir mg fda previously granted two breakthrough therapy designations zepatier treatment chronic hcv gt infection patients end stage renal disease hemodialysis treatment patients chronic hcv gt infection breakthrough therapy designation given investigational medicines serious lifethreatening conditions may offer substantial improvement existing therapies across multiple clinical studies zepatier achieved high rates sustained virologic response ranging gtinfected patients gtinfected patients sustained virologic response defined hcv rna levels measuring less lower limit quantification weeks cessation treatment indicating patients hcv infection cured zepatier became available united states february zepatier review eu hiv worldwide sales isentress hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection billion decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states lower demand pricing europe due competitive pressures partially offset higher volumes latin america higher pricing united states global sales isentress increased billion compared primarily reflecting volume growth europe emerging markets particularly latin america resulting government tenders partially offset volume declines united states reflecting competitive pressures foreign exchange unfavorably affected global sales performance hospital acute care january merck acquired cubist leader development therapies treat serious infections caused broad range bacteria cubists products include cubicin iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms sales cubicin billion subsequent acquisition us composition patent cubicin expires june significant losses cubicin sales expected occur thereafter many markets outside united states cubicin commercialized companies accordance distribution agreements established prior mercks acquisition cubist fourth quarter merck entered agreements reacquire marketing rights cubicin certain international markets including europe latin america australia new zealand china south africa certain asia pacific countries cubists products also include zerbaxa combination product approved fda december treatment adults complicated urinary tract infections caused designated susceptible gramnegative organisms complicated intraabdominal infections caused designated susceptible gramnegative grampositive organisms sivextro product approved fda june treatment acute bacterial skin skin structure infections absssi adults caused designated susceptible grampositive organisms sivextro also approved ec march treatment absssi adults company began launching sivextro second quarter september zerbaxa approved ec treatment complicated intraabdominal infections acute pyelonephritis complicated urinary tract infections adults zerbaxa sivextro phase development united states treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia global sales cancidas antifungal product million decrease compared reflecting unfavorable effect foreign exchange volume declines certain emerging markets worldwide sales cancidas grew million compared largely reflecting volume growth asia pacific region particularly china foreign exchange unfavorably affected global sales performance worldwide sales noxafil prevention invasive fungal infections grew million increased million driven pricing higher demand united states volume growth europe reflecting positive impact approval new formulations foreign exchange unfavorably affected global sales performance table contents sales bridion reversal two types neuromuscular blocking agents used surgery grew million rose million driven volume growth international markets sold foreign exchange unfavorably affected global sales performance bridion approved marketed many countries outside united states december fda approved bridion reversal neuromuscular blockade induced rocuronium bromide vecuronium bromide adults undergoing surgery immunology sales remicade treatment inflammatory diseases marketed company europe russia turkey billion decline compared including unfavorable effect foreign exchange february company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition company retained majority existing patients company lost market share new patients prescribed biosimilars company expects remicade sales decline accelerate throughout sales remicade billion increase compared reflecting sales growth europe partially offset decline russia sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey million essentially flat compared driven higher demand europe reflecting part ongoing positive impact ulcerative colitis indication offset unfavorable effect foreign exchange sales simponi grew million compared driven demand europe reflecting part positive impact ulcerative colitis indication products contained hospital specialty include among others invanz treatment certain infections primaxin antibacterial product oncology sales keytruda antipd programmed death receptor therapy million million increase primarily reflects higher sales united states well emerging markets europe company continues launch keytruda september fda granted accelerated approval keytruda dose mgkg every three weeks treatment patients unresectable metastatic melanoma disease progression following ipilimumab braf v mutation positive braf inhibitor december company announced fda approved expanded indication keytruda include firstline treatment patients unresectable metastatic melanoma regardless braf status additionally fda approved update product labeling keytruda treatment patients ipilimumabrefractory advanced melanoma addition october fda granted accelerated approval keytruda dose mgkg every three weeks treatment patients metastatic nsclc whose tumors express pdl determined fdaapproved test disease progression platinumcontaining chemotherapy across squamous nonsquamous metastatic nsclc patients egfr alk genomic tumor aberrations disease progression fdaapproved therapy aberrations prior receiving keytruda addition approving keytruda nsclc fda approved first companion diagnostic enable physicians determine level pdl expression patients tumor july merck announced ec approved keytruda treatment advanced unresectable metastatic melanoma adults october merck announced national institute health care excellence nice uk issued draft recommendation form final appraisal determination recommending keytruda firstline treatment option adults advanced melanoma addition nice issued final guidance recommending keytruda treatment advanced melanoma disease progression ipilimumab company made additional regulatory filings countries filings planned keytruda clinical development program includes studies across broad range cancer types see research development table contents global sales emend prevention chemotherapyinduced postoperative nausea vomiting million decline reflecting unfavorable effect foreign exchange partially offset higher pricing united states volume growth europe worldwide sales emend million increase compared including unfavorable effect foreign exchange largely reflecting volume growth regions february merck announced fda approved supplemental new drug application singledose emend injection prevention delayed nausea vomiting adults receiving initial repeat courses moderately emetogenic chemotherapy approval emend injection first intravenous singledose nk receptor antagonist approved united states highly emetogenic chemotherapy well moderately emetogenic chemotherapy sales temodar marketed temodal outside united states treatment certain types brain tumors million decline compared reflecting unfavorable effect foreign exchange partially offset growth emerging markets global sales temodar declined million foreign exchange unfavorably affected global sales performance sales decline driven primarily generic competition united states well europe agreement generic manufacturer launched generic version temodar united states august us patent exclusivity periods otherwise expired february diversified brands mercks diversified brands include human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world respiratory worldwide sales singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis million decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes japan lower demand europe result generic competition global sales singulair billion decline compared including unfavorable effect foreign exchange primarily reflecting lower sales europe result generic competition company lost market exclusivity singulair united states major international markets exception japan expects generic competition markets continue patent provides market exclusivity singulair japan expire singulair sales japan million global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms million decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states reflecting competition alternative generic treatment options well supply constraints supply issue resolved nasonex became available october addition lower volumes pricing europe ongoing generic erosion also contributed nasonex sales decline agreement generic manufacturers able launch generic version nasonex european markets january generic versions nasonex since launched markets accordingly company continues experience volume pricing declines nasonex sales europe worldwide sales nasonex decreased billion compared foreign exchange unfavorably affected global sales performance sales decline driven primarily lower demand united states well lower volumes europe canada resulting generic competition apotex inc apotex corp collectively apotex filed application fda seeking approval sell generic version nasonex june us district court district new jersey ruled company patent infringement suit apotex holding apotexs generic version nasonex infringe companys formulation patent june court appeals federal circuit issued decision affirming us district court decision company exhausted appeal options apotex yet launched generic version nasonex united states however apotexs generic version becomes available significant losses us nasonex sales could occur us sales nasonex million table contents global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatments hypertension declined million decreased million foreign exchange unfavorably affected global sales performance respectively patents provided market exclusivity cozaar hyzaar united states major international markets expired accordingly company experiencing declines cozaar hyzaar sales expects declines continue worldwide sales ophthalmic products cosopt trusopt million million million declines driven largely divestiture cosopt trusopt many international markets addition sale us rights cosopt cosopt pf also contributed sales decline compared december company divested remaining ophthalmics portfolio international markets mundipharma ophthalmology products limited see note consolidated financial statements products contained diversified brands include among others clarinex nonsedating antihistamine arcoxia treatment arthritis pain company markets outside united states fosamax marketed fosamac japan fosamax plus marketed fosavance throughout eu treatment case fosamax prevention osteoporosis zocor statin modifying cholesterol propecia product treatment male pattern hair loss vaccines following discussion vaccines include sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates included income expense net see selected joint venture affiliate information supply sales spmsd however included mercks sales gardasilgardasil vaccines help prevent certain diseases caused certain types hpv billion increase compared including unfavorable effect foreign exchange sales growth driven primarily higher sales united states resulting higher pricing increased volumes reflecting timing public sector purchases well increased government tenders asia pacific region partially offset declines latin america due price volume gardasil mercks valent hpv vaccine approved fda december use girls young women years age gardasil includes greatest number hpv types available hpv vaccine december fda approved expanded age indication gardasil include use males years age prevention anal cancers precancerous dysplastic lesions genital warts caused certain hpv types mercks sales gardasil billion decline compared including unfavorable effect foreign exchange decline reflects lower sales asia pacific japan canada partially offset higher government tenders brazil national immunization program well higher public sector purchases united states sales included million million respectively purchases us centers disease control prevention cdc pediatric vaccine stockpile company party certain third party license agreements respect gardasilgardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasilgardasil sales vary country included materials production costs mercks sales proquad pediatric combination vaccine help protect measles mumps rubella varicella million million million sales growth compared driven higher sales united states reflecting increased volumes driven part measles outbreaks united states well higher pricing increase compared driven primarily higher sales united states reflecting approximately million government purchases cdc pediatric vaccine stockpile mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales growth compared driven higher demand resulting measles outbreaks united states higher pricing table contents mercks sales varivax vaccine help prevent chickenpox varicella million million million sales growth compared reflects higher volumes certain emerging markets higher pricing united states partially offset lower volumes united states sales performance compared reflects lower sales united states largely offset growth emerging markets mercks sales zostavax vaccine help prevent shingles herpes zoster adults years age older million decline compared including unfavorable effect foreign exchange sales performance compared reflects lower volumes united states partially offset higher demand canada higher pricing united states mercks sales zostavax million increase compared driven primarily higher sales asia pacific region due ongoing launches partially offset lower demand united states well canada company continuing educate us customers broad managed care coverage zostavax process obtaining reimbursement merck continuing launch zostavax outside united states mercks sales rotateq vaccine help protect rotavirus gastroenteritis infants children million decline compared including unfavorable effect foreign exchange decline driven primarily effects public sector purchasing united states mercks sales rotateq increased million compared primarily reflecting higher sales certain emerging markets mercks sales pneumovax vaccine help prevent pneumococcal disease declined million compared driven primarily lower demand united states due near term market dynamics sales emerging markets mercks sales pneumovax grew million compared driven primarily higher sales japan national immunization program well higher sales united states attributable price volume foreign exchange unfavorably affected sales performance respectively segments companys segments animal health alliances healthcare services segments material separate reporting prior disposition october company also consumer care segment sales billion billion animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected competition frequent introduction generic products global sales animal health products billion decline compared including unfavorable effect foreign exchange sales performance reflects volume growth companion animal products driven primarily higher sales bravecto chewable tablets dogs treat fleas ticks began launching europe united states well volume growth swine aqua products worldwide sales animal health products totaled billion growth compared including unfavorable effect foreign exchange sales growth driven primarily higher sales companion animal products reflecting launch bravecto europe united states well higher sales poultry aqua products partially offset lower sales zilmax feed supplement beef cattle alliances alliances segment includes results companys relationship azlp june astrazeneca exercised option buy mercks interest subsidiary mercks interest nexium prilosec result july company longer records equity income azlp supply sales azlp primarily relating sales nexium prilosec terminated see selected joint venture affiliate information revenue azlp million june termination date million table contents costs expenses millions change change materials production marketing administrative research development restructuring costs income expense net greater includes million million million iprd impairment charges respectively materials production materials production costs billion billion billion costs include expenses amortization intangible assets recorded connection business acquisitions totaled billion billion billion addition expenses include million amortization purchase accounting adjustments cubists inventories costs also include intangible asset impairment charges million billion million respectively related marketed products intangibles see note consolidated financial statements company may recognize additional noncash impairment charges future related intangibles measured fair value capitalized connection acquisitions charges could material additionally costs include million intangible asset impairment charge related licensing agreement also included materials production costs associated restructuring activities amounted million million million respectively including accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared amortization intangible assets purchase accounting adjustments inventories well restructuring impairment charges noted reduced gross margin percentage points percentage points percentage points excluding impacts gross margin improvement compared driven primarily favorable effects foreign exchange lower inventory writeoffs well net impact acquisitions divestitures gross margin decline compared driven primarily unfavorable effects inventory writeoffs largely related victrelis well changes product mix partially offset sale us marketing rights saphris marketing administrative marketing administrative expenses declined billion largely reflecting favorable effects foreign exchange prior year divestiture mcc additional expenses prior year related health care reform fee discussed lower restructuring costs well lower selling costs partially offset higher promotional spending largely related product launches well higher costs related january acquisition cubist higher acquisition divestiturerelated costs marketing administrative expenses decreased billion driven primarily lower selling costs promotional spending divestiture mcc favorable effects foreign exchange partially offset additional year expense related health care reform fee well higher acquisition divestiturerelated costs expenses include restructuring costs million million million respectively related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed expenses also include million million million acquisition divestiturerelated costs respectively consisting integration transaction certain costs related business acquisitions including severance costs part companys formal restructuring programs well transaction certain costs related divestitures table contents july irs issued final regulations annual nontax deductible health care reform fee imposed patient protection affordable care act based allocation companys market share prior year branded pharmaceutical sales certain government programs final irs regulations accelerated recognition criteria fee obligation one year year underlying sales used allocate fee occurred rather year fee paid result change merck recorded additional year expense million research development research development expenses billion decline compared billion driven primarily favorable effects foreign exchange expenses recognized prior year increase estimated fair value liabilities contingent consideration lower restructuring costs charge prior year related collaboration bayer ag bayer prior year divestiture mcc partially offset acquisition cubist higher licensing costs higher clinical development spending research development expenses declined billion compared billion reflecting targeted reductions lower clinical development spend result portfolio prioritization cost savings resulting restructuring activities lower acquired inprocess research development iprd impairment charges partially offset higher charges increase estimated fair value liabilities contingent consideration higher restructuring costs charge related collaboration bayer research development expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities approximately billion billion billion also included research development expenses costs incurred divisions support research development activities including depreciation production general administrative well licensing activity certain costs operating segments including pharmaceutical animal health segments aggregate billion billion billion respectively research development expenses also include iprd impairment charges million million million respectively see research development company may recognize additional noncash impairment charges future cancellation delay pipeline programs measured fair value capitalized connection acquisitions charges could material addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection acquisitions company recorded reduction expenses million decrease fair value liabilities contingent consideration recorded charge million increase estimated fair value liabilities contingent consideration see note consolidated financial statements research development expenses also reflect million million million respectively accelerated depreciation asset abandonment costs associated restructuring activities restructuring costs restructuring costs primarily representing separation related costs associated restructuring activities million billion billion respectively costs include million million million respectively expenses related restructuring program remaining costs nearly remaining costs recorded related merger restructuring program separation costs million million billion respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated positions eliminated restructuring program approximately positions eliminated merger restructuring program approximately position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development discussed table contents income expense net income expense net billion expense compared billion income unfavorability driven primarily gains recognized including billion gain related divestiture mcc see note consolidated financial statements million gain related astrazenecas option exercise see note consolidated financial statements million gain divestiture certain ophthalmic products several international markets see note consolidated financial statements million gain related divestiture companys sirna therapeutics inc subsidiary see note consolidated financial statements unfavorability also driven million net charge recorded related settlement vioxx shareholder class action litigation see note consolidated financial statements foreign exchange losses million related devaluation companys net monetary assets venezuela see note consolidated financial statements lower equity income azlp partially offsetting unfavorability items million loss extinguishment debt see note consolidated financial statements million gain sale certain migraine clinical development programs see note consolidated financial statements million gain divestiture companys remaining ophthalmics business international markets see note consolidated financial statements higher equity income certain research investment funds million goodwill impairment charge related companys joint venture supera see note consolidated financial statements income expense net billion income compared million expense driven primarily gains recognized noted lower foreign exchange losses due venezuelan currency devaluation partially offset charges recognized related extinguishment debt goodwill impairment noted well lower equity income azlp segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment sales less standard costs certain operating expenses directly incurred segment components equity income loss affiliates certain depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits acquisition divestiturerelated costs including amortization purchase accounting adjustments intangible asset impairment charges restructuring costs taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items including gains divestitures net charge related settlement vioxx shareholder class action litigation gain astrazenecas option exercise foreign exchange losses related devaluation companys net monetary assets venezuela loss extinguishment debt additional year expense related health care reform fee reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales pharmaceutical segment profits declined compared primarily reflecting unfavorable effect foreign exchange pharmaceutical segment profits declined compared driven primarily unfavorable effects product divestitures loss market exclusivity certain products partially offset cost savings productivity measures declines segment profits reflect termination companys relationship azlp well divestiture mcc table contents taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs restructuring costs partially offset beneficial impact foreign earnings effective income tax rate also reflects favorable impact net benefit million related settlement certain federal income tax issues impact net charge related settlement vioxx shareholder class action litigation fully deductible combined us federal state tax rates favorable impact tax legislation enacted fourth quarter well unfavorable effect nontax deductible foreign exchange losses related venezuela see note consolidated financial statements effective income tax rate reflects impact gain divestiture mcc taxed combined us federal state tax rates addition effective income tax rate includes net tax benefit million recorded connection astrazenecas option exercise see note consolidated financial statements benefit approximately million associated capital loss generated connection sale sirna see note consolidated financial statements effective income tax rate also includes unfavorable impact additional year expense nontax deductible health care reform fee company recorded accordance final regulations issued third quarter irs effective income tax rate reflects net benefit million settlements certain federal income tax issues net benefits reductions tax reserves upon expiration applicable statutes limitations favorable impact tax legislation enacted first quarter extended rd tax credit well outof period net tax benefit approximately million associated resolution previously disclosed legacy scheringplough federal income tax issue see note consolidated financial statements company examination numerous tax authorities various jurisdictions globally ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures however one item currently discussion irs relating examination company concluded position sustained upon audit however item result unfavorable outcome settlement could material adverse impact companys financial position liquidity results operations net income attributable noncontrolling interests net income attributable noncontrolling interests million million million declines compared reflect part termination companys relationship azlp resulting retirement kbi preferred stock see note consolidated financial statements addition amount includes portion intangible asset goodwill impairment charges related companys joint venture supera see note consolidated financial statements attributable noncontrolling interests net income earnings per common share net income attributable merck co inc billion billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance used management merck providing management believes information enhances investors understanding companys results nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance therefore information nongaap income nongaap eps considered addition lieu net income eps prepared accordance generally accepted accounting principles united states gaap additionally since nongaap income non gaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies table contents nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap income nongaap eps performance company measured basis along performance metrics senior managements annual compensation derived part using nongaap income nongaap eps reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts pretax income reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain sale certain migraine clinical development programs gain divestiture certain ophthalmic products gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt additional year expense health care reform fee taxes income reported gaap estimated tax benefit provision excluded items net tax benefits settlements federal income tax issues tax benefits related sale sirna therapeutics inc subsidiary nongaap net income less net income attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution amount includes net benefit million recorded connection astrazenecas option exercise represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement contingent consideration also excluded integration transaction certain costs associated business acquisitions including severance costs part table contents companys formal restructuring programs well transaction certain costs related divestitures costs considered non recurring however management excludes amounts nongaap income nongaap eps believes helpful understanding performance continuing business restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment shut related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs company undertaken restructurings different types covered periods therefore charges considered nonrecurring however management excludes amounts nongaap income nongaap eps believes helpful understanding performance continuing business certain items nongaap income nongaap eps exclude certain items items represent substantive unusual items evaluated individual basis evaluation considers quantitative qualitative aspect unusual nature generally represent items either result nature magnitude management would anticipate would occur part companys normal business regular basis excluded nongaap income nongaap eps foreign exchange losses related devaluation companys net monetary assets venezuela see note consolidated financial statements net charge related settlement vioxx shareholder class action litigation see note consolidated financial statements gain sale certain migraine clinical development programs see note consolidated financial statements gain divestiture companys remaining ophthalmics business international markets see note consolidated financial statements well net tax benefit related settlement certain federal income tax issues see note consolidated financial statements excluded nongaap income nongaap eps certain gains including gain divestiture mcc see note consolidated financial statements gain recognized conjunction astrazenecas option exercise including related net tax benefit transaction see note consolidated financial statements gain divestiture certain ophthalmic products several international markets see note consolidated financial statements well loss extinguishment debt see note consolidated financial statements additional year expense related health care reform fee discussed tax benefit sale sirna tax benefits settlements certain federal income tax issues see note consolidated financial statements research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states internationally keytruda fdaapproved antipd programmed death receptor therapy clinical development expanded indications different cancer types keytruda currently approved treatment melanoma advanced melanoma nsclc see pharmaceutical segment december merck announced results pivotal keynote study evaluate potential immunotherapy compared chemotherapy based prospective measurement pdl expression patients advanced nsclc phase study keytruda significantly improved overall survival compared chemotherapy patients level pdl expression based data merck submitted supplemental biologics license application fda filed marketing authorization application ema table contents november merck announced fda granted breakthrough therapy designation keytruda treatment patients microsatellite instability high metastatic colorectal cancer fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints keytruda previously granted breakthrough therapy status advanced melanoma advanced nsclc keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck melanoma multiple myeloma non smallcell lung triple negative breast several currently phase clinical development mk bezlotoxumab investigational antitoxin prevention c difficile infection recurrence currently review fda ema january merck announced fda accepted review biologics license application bla bezlotoxumab granted priority review prescription drug user fee act action date july september merck announced two pivotal phase clinical studies bezlotoxumab met primary efficacy endpoint reduction c difficile recurrence week compared placebo used conjunction standard care antibiotics treatment c difficile company also seeking approval eu intends file canada currently therapies approved prevention recurrent disease caused c difficile mk insulin glargine candidate treatment patients type type diabetes developed collaboration samsung bioepis december company submitted application regulatory approval eu plans submit mk fda mka zepatier currently review eu treatment chronic hcv oncedaily fixeddose combination tablet containing nsa inhibitor elbasvir mg nsa protease inhibitor grazoprevir mg zepatier approved fda january treatment adult patients chronic hcv gt gt infection without ribavirin v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized partnership merck sanofi pasteur vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b november fda issued crl respect bla v companies reviewing crl plan communication fda february ec granted marketing authorization v prophylaxis diphtheria tetanus pertussis hepatitis b poliomyelitis invasive disease caused hib infants toddlers age weeks v marketed vaxelis eu spmsd companys joint venture sanofi pasteur addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed company anticipates filing applications regulatory approval fda respect certain candidates including mk noted mk odanacatib oral onceweekly investigational treatment patients osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis september merck announced data pivotal phase fracture outcomes study odanacatib postmenopausal women osteoporosis longterm odanacatib fracture trial loft odanacatib met primary endpoints significantly reduced risk three types osteoporotic fractures radiographicallyassessed vertebral clinical hip clinical nonvertebral compared placebo also reduced risk secondary endpoint clinical vertebral fractures addition treatment odanacatib led progressive increases five years bone mineral density lumbar spine total hip rates adverse events overall loft generally balanced patients table contents taking odanacatib placebo adjudicated events morphealike skin lesions atypical femoral fractures occurred often odanacatib group placebo group adjudicated major adverse cardiovascular events generally balanced overall treatment groups numerically adjudicated stroke events odanacatib placebo adjudicated atrial fibrillation reported often odanacatib group placebo group numeric imbalance mortality observed numeric difference appear related particular reported cause causes death merck continues collect data blinded extension study planning additional analyses data trial including independent readjudication major adverse cardiovascular events mace support regulatory submissions merck plans submit new drug application nda fda odanacatib following completion independent adjudication analysis mace merck also plans submit applications ema ministry health labour welfare japan mk omarigliptin investigational onceweekly dpp inhibitor development treatment adults type diabetes september company announced omarigliptin achieved primary efficacy endpoint phase study omarigliptin found noninferior januvia reducing patients ac estimate persons blood glucose twoto threemonth period levels baseline similar ac reductions achieved groups headtohead study designed evaluate onceweekly treatment omarigliptin mg compared mg januvia daily results presented oral session st european association study diabetes annual meeting also september merck announced japanese pharmaceuticals medical devices agency approved marizev omarigliptin mg mg tablets japan first country approved omarigliptin merck plans submit omarigliptin regulatory approval united states worldwide regulatory submissions follow mk ertugliflozin investigational oral sglt inhibitor evaluated treatment type diabetes collaboration pfizer inc ertugliflozin also studied combination januvia sitagliptin metformin merck expects submit applications regulatory approval united states ertugliflozin two fixeddose combination tablets end mk investigational allergy immunotherapy tablet house dust mite allergy part north america partnership merck alkabello merck plans submit nda fda mk first half mk verubecestat mercks novel investigational oral amyloid precursor protein sitecleaving enzyme bace inhibitor treatment alzheimers disease studied phase trial apecs designed evaluate safety efficacy mk versus placebo patients amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease mk also studied another phase randomized placebocontrolled study patients mildtomoderate alzheimers disease epoch epoch study completed enrollment fourth quarter estimated reach primary trial completion mid mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raising hdlc reducing ldl c anacetrapib evaluated patient eventdriven cardiovascular clinical outcomes trial sponsored oxford university reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease projected conclude early november merck announced data monitoring committee dmc reveal outcomes study completed planned review unblinded study data recommended study continue changes dmc reviewed safety efficacy data study included assessment futility merck remains blinded actual results analysis reveal safety efficacy data reveal steering committee merck continue monitor progress study additional interim efficacy analyses planned mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qualified infectious disease product designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections table contents mk letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir received orphan drug status eu united states also granted fast track designation mkb referred next generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea women seeking contraception mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor codeveloped astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials currently underway west africa november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola procedure intended assist united nations procurement agencies member states acceptability using vaccine candidate emergencyuse setting eual designation prequalification rather special procedure implemented outbreak disease high rates morbidity andor mortality lack treatment andor prevention options instances may recommend making vaccine available limited time clinical trial data gathered formal regulatory agency review national regulatory authority decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution v inactivated varicella zoster virus vaccine development prevention herpes zoster company conducting two phase trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies mk doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor developed merck treatment hiv infection company also divested discontinued certain drug candidates july merck allergan plc allergan entered agreement pursuant allergan acquired exclusive worldwide rights mk mk mercks investigational small molecule oral cgrp receptor antagonists developed treatment prevention migraine see note consolidated financial statements mk surotomycin investigational oral antibiotic development treatment c difficile associated diarrhea merck acquired surotomycin part purchase cubist second quarter company received unfavorable efficacy data randomized doubleblinded activecontrolled study patients c difficile associated diarrhea evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge see note consolidated financial statements mk bevenopran oral investigational therapy development potential treatment opioidinduced constipation patients chronic noncancer pain merck acquired bevenopran part purchase cubist company made decision continue development program seeking outlicense asset mk corifollitropin alfa injection investigational fertility treatment controlled ovarian stimulation women participating assisted reproductive technology july merck received crl fda nda corifollitropin alfa injection merck made decision discontinue development corifollitropin alfa injection united states business reasons corifollitropin alfa injection marketed elonva certain markets outside united states table contents company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed making externally sourced programs greater component pipeline strategy renewed focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases neurodegenerative diseases osteoporosis respiratory diseases womens health acquired inprocess research development connection acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion amount billion relates clinical development program mk company acquired acquisition idenix pharmaceuticals inc idenix approximately million million million respectively iprd projects received marketing approval major market company began amortizing assets based estimated useful lives iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date company may also recover research development expenditures made since acquisition develop program circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded million iprd impairment charges within research development expenses amount million relates surotomycin clinical development program obtained connection acquisition cubist company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted company recorded million iprd impairment charges primarily result changes cash flow assumptions certain compounds obtained connection supera joint venture well discontinuation certain animal health programs company recorded million iprd impairment charges amount million related writeoff intangible asset associated preladenant result discontinuation clinical development program compound addition company recorded impairment charges resulting changes cash flow assumptions certain compounds well pipeline programs previously deprioritized subsequently deemed alternative use period additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought table contents final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects acquired connection acquisitions phase development human health analogous stage development animal health approximately million acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent significant transactions described merck actively monitoring landscape growth opportunities meet companys strategic criteria january merck acquired iomet privately held ukbased drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism total purchase consideration transaction included upfront cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved acquisition provides merck iomets preclinical pipeline ido indoleaminedioxygenase tdo tryptophan dioxygenase dualacting idotdo inhibitors company process determining preliminary fair value assets acquired liabilities assumed total consideration transferred business acquisition transaction closed january accordingly results operations acquired business included companys results operations beginning date july merck acquired ccam privately held biopharmaceutical company focused discovery development novel cancer immunotherapies acquisition provides merck ccams lead pipeline candidate cm novel monoclonal antibody targeting immune checkpoint protein ceacam evaluated phase study treatment advanced recurrent malignancies including melanoma nonsmallcell lung bladder gastric colorectal ovarian cancers total purchase consideration transaction million included upfront payment million cash future additional payments million associated attainment certain clinical development regulatory commercial milestones company determined fair value million acquisition date transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date merck recognized intangible asset iprd million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflects stage development project associated probability successful completion assets probabilityadjusted future net cash flows discounted present value using discount rate fair value contingent consideration determined utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment also utilizing discount rate actual cash flows likely different assumed transaction closed july accordingly results operations acquired business included companys results operations beginning date february merck ngm privately held biotechnology company entered multiyear collaboration research discover develop commercialize novel biologic therapies across wide range therapeutic areas collaboration includes multiple drug candidates currently preclinical development ngm including np evaluated treatment diabetes obesity nonalcoholic steatohepatitis ngm lead research development existing preclinical candidates autonomy identify pursue discovery stage programs discretion merck option license resulting ngm programs following human proof concept trials merck exercises option merck lead global product development commercialization resulting products approved terms agreement merck made upfront payment ngm million included research development expenses purchased equity stake ngm million merck committed million fund ngms efforts initial fiveyear term collaboration potential additional funding certain conditions met prior merck initiating phase study licensed program ngm may elect either receive milestone royalty payments certain cases cofund development participate global cost revenue share arrangement table contents agreement also provides ngm option participate copromotion cofunded program united states merck option extend research agreement two additional twoyear terms party certain termination rights agreement event uncured material breach party additionally merck certain termination rights event occurrence certain defined conditions upon termination event depending circumstances parties varying rights obligations respect continued development commercialization compounds discovered agreement certain related payment obligations january merck acquired cubist leader development therapies treat serious infections caused broad range bacteria total consideration billion see note consolidated financial statements transaction closed january accordingly results operations acquired business included companys results operations beginning date estimated fair values identifiable intangible assets related currently marketed products determined using income approach companys estimates projected net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed significant intangible assets relate zerbaxa cubicin sivextro company recorded fair value incomplete research project surotomycin mk time acquisition reached technological feasibility alternative future use amount capitalized accounted indefinitelived intangible asset subject impairment testing completion abandonment project fair value surotomycin determined using income approach probabilityadjusted future net cash flows discounted present value using discount rate second quarter company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge connection cubist acquisition liabilities recorded potential future consideration contingent upon achievement future salesbased milestones fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows changes inputs could result different fair value measurement selected joint venture affiliate information astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights merck earned revenue based sales kbi products revenue million million primarily relating sales nexium well prilosec addition merck earned certain partnership table contents returns azlp million million recorded equity income affiliates june astrazeneca exercised option purchase mercks interest kbi million cash amount million reflects estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june deferred recognized time income expense net contingency eliminated sales occur million million respectively deferred income recognized bringing cumulative deferred income recognized december million remaining exercise price million primarily represents multiple ten times mercks average annual profit allocation partnership three years prior exercise merck recognized million gain within income expense net result astrazenecas option exercise companys remaining interest azlp redeemed accordingly company also recognized noncash gain approximately million within income expense net resulting retirement billion kbi preferred stock see note consolidated financial statements elimination companys billion investment azlp million reduction goodwill transaction resulted net tax benefit million primarily reflecting reversal deferred taxes azlp investment balance result astrazeneca exercising option july company longer records equity income azlp supply sales azlp terminated sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions gardasil influenza vaccines zostavax viral vaccines rotateq hepatitis vaccines vaccines simcere msd shanghai pharmaceutical co ltd march merck simcere pharmaceutical co ltd simcere executed restructuring agreement merck agreed transfer ownership interest simcere msd shanghai pharmaceutical co ltd joint venture simcere result merck deconsolidated joint venture recorded net loss million income expense net capital expenditures capital expenditures billion billion billion expenditures united states million million million depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements table contents analysis liquidity capital resources mercks strong financial profile enables fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion decline cash provided operating activities compared reflects approximately billion taxes paid divestiture mcc cash provided operating activities includes payment made company million connection settlement enhance litigation cash provided operating activities continues companys primary source funds finance operating needs capital expenditures portion treasury stock purchases dividends paid shareholders cash used investing activities billion compared million primarily reflecting cash received divestiture mcc higher cash received dispositions businesses connection astrazenecas option exercise well cash used acquisition cubist partially offset lower purchases securities investments higher proceeds sales securities investments cash used acquisition idenix cash payment made upon formation collaboration bayer cash used investing activities million compared billion reflecting cash received divestiture mcc dispositions businesses well cash received connection astrazenecas option exercise partially offset higher purchases lower proceeds sale securities investments cash used acquisition idenix cash payment made upon formation collaboration bayer cash used financing activities billion compared billion driven primarily higher proceeds issuance debt lower payments debt lower purchases treasury stock partially offset lower proceeds exercise stock options decrease shortterm borrowings cash used financing activities billion compared billion driven primarily higher payments debt lower proceeds issuance debt higher purchases treasury stock decrease shortterm borrowings partially offset higher proceeds exercise stock options company recorded charges million related devaluation net monetary assets venezuela large majority cash see note consolidated financial statements december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments generally cash investments held foreign subsidiaries would subject significant tax payments cash investments repatriated form dividends company records us deferred tax liabilities certain unremitted earnings amounts earned overseas expected indefinitely reinvested outside united states accrual us taxes provided amount cash investments held us foreign subsidiaries fluctuates due variety factors including timing receipt payments normal course business cash provided operating activities united states continues companys primary source funds finance domestic operating needs capital expenditures portion treasury stock purchases dividends paid shareholders table contents companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations vioxx shareholder class action settlement reserve unrecognized tax benefits operating leases includes future bulk supply purchases company committed connection certain divestitures january million debt matured repaid company anticipates receiving insurance proceeds approximately million partially fund liability see note consolidated financial statements december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including billion reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments also excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million us pension plans million international pension plans million postretirement benefit plans august company terminated existing credit facility entered billion fiveyear credit facility matures august facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility february merck issued billion aggregate principal amount senior unsecured notes consisting million principal amount floating rate notes due million principal amount floating rate notes due billion principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due company used portion net proceeds offering billion repay commercial paper issued substantially finance companys acquisition cubist remaining net proceeds used general corporate purposes including repurchases companys common stock repayment outstanding commercial paper borrowings debt maturities also february company redeemed billion legacy cubist debt acquired acquisition see note consolidated financial statements december company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee table contents existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november board directors declared quarterly dividend per share companys common stock payable january march mercks board directors authorized additional purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions company purchased billion common stock million shares treasury company approximately billion remaining march share repurchase program company purchased billion billion common stock respectively previously authorized share repurchase programs financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates primary objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premiums writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated table contents foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar would yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level cash flows contracts reported operating activities consolidated statements cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income taxes would declined approximately million million company net long receivable position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations february venezuelan government devalued currency bolvar fuertes vef per us dollar vef per us dollar company recognized losses due exchange approximately million resulting remeasurement local monetary assets liabilities new rate addition official rate vef per us dollar venezuelan government maintains two official rates sistema complementario de administracion de divisas sicad sistema marginal de divisas simadi sicad simadi average rates published central bank venezuela december average exchange rates inferred vef per us dollar vef per us dollar respectively historically venezuelan government indicated essential goods including food medicine would remain official rate vef per us dollar table contents second quarter upon evaluation evolving economic conditions venezuela volatility country combined decline transactions settled official rate company determined unlikely outstanding net monetary assets would settled official rate accordingly second quarter company recorded charge million within income expense net devalue net monetary assets venezuela amount represented companys estimate us dollar amount would ultimately collected third quarter company recorded additional exchange losses million reflecting ongoing effect translating transactions net monetary assets consistent second quarter result deterioration economic conditions venezuela continued declines transactions settled official rate fourth quarter company began using simadi rate report venezuelan operations company also revalued remaining net monetary assets simadi rate resulted additional charge fourth quarter million accordingly december company approximately million us dollar equivalent simadi rate remaining net monetary assets venezuelan entities large majority cash mercks sales venezuela approximately million company reduced operations venezuela however merck continues work government venezuela import essential medicines country result transitioning simadi rate fourth quarter purposes reporting venezuelan operations merck anticipates sales venezuela de minimis company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income oci remains accumulated comprehensive income aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes table contents swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurement additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions determine whether acquisitions qualify business combinations asset acquisitions company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines acquisition consists inputs well processes applied inputs ability create outputs acquisition determined business combination business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement table contents performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations company determines transaction accounted acquisition business transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense acquisition date fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized title risk loss passes customer typically time delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts customers collection accounts receivable expected excess one year provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis table contents comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements table contents inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year table contents sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension postretirement benefit plans totaled million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension postretirement benefit plans largely attributable changes discount rate affecting net amortization company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forward looking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return range range us pension postretirement benefit plans company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements table contents net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized market related value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed reduce cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired assigned reporting units company tests goodwill impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price additionally company evaluates extent fair value exceeded carrying value reporting unit last date valuation performed company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles excluding iprd recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely table contents fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthan temporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability recently issued accounting standards may financial accounting standards board fasb issued amended accounting guidance revenue recognition applied contracts customers objective new guidance improve table contents comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements august fasb approved oneyear deferral effective date making guidance effective interim annual periods beginning reporting entities may choose adopt standard original effective date company currently assessing impact adoption consolidated financial statements april fasb issued accounting guidance requires debt issuance costs presented direct deduction carrying amount debt balance sheet opposed presented deferred charge new guidance effective interim annual periods beginning december company debt issuance costs recorded deferred charges approximately million january fasb issued revised guidance accounting reporting financial instruments new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income new guidance also simplifies impairment testing equity investments without readily determinable fair values changes certain disclosure requirements guidance effective interim annual periods beginning early adoption permitted company currently assessing impact adoption consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive income loss net taxes net unrealized loss gain derivatives net reclassifications net unrealized loss gain investments net reclassifications benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts excludes accounts receivable classified assets see note inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased supera joint venture formation net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net tax cash dividends declared common stock per share treasury stock shares purchased astrazeneca option exercise net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased changes noncontrolling ownership interests net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain divestiture merck consumer care business gain astrazeneca option exercise loss extinguishment debt equity income affiliates dividends distributions equity method affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments divestiture merck consumer care business net cash divested dispositions businesses net cash divested proceeds astrazeneca option exercise acquisition cubist pharmaceuticals inc net cash acquired acquisition idenix pharmaceuticals inc net cash acquired acquisitions businesses net cash acquired acquisition bayer ag collaboration rights cash inflows net investment hedges net cash used investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health alliances healthcare services segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients january company acquired cubist pharmaceuticals inc cubist july merck acquired ccam biotherapeutics ltd ccam results cubists ccams businesses included mercks financial statements subsequent respective acquisition dates see note october company divested consumer care segment developed manufactured marketed overthecounter foot care sun care products see note summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet table contents definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair values companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci declines fair value equity securities considered otherthan temporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized title risk loss passes customer typically upon delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission table contents guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multiyear implementation enterprisewide resource planning system million million net accumulated amortization december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development acquired inprocess research development iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event risk table contents adjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life amounts due collaborative partners related development activities generally reflected reduction research development expenses specific milestone achieved nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges periods addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation table contents recently adopted accounting standards november financial accounting standards board fasb issued accounting guidance balance sheet classification deferred taxes part simplification initiative aimed reducing complexity accounting standards new guidance requires deferred tax assets liabilities along related valuation allowance classified noncurrent balance sheet company elected early adopt new guidance fourth quarter see note recently issued accounting standards may fasb issued amended accounting guidance revenue recognition applied contracts customers objective new guidance improve comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements august fasb approved oneyear deferral effective date making guidance effective interim annual periods beginning reporting entities may choose adopt standard original effective date company currently assessing impact adoption consolidated financial statements april fasb issued accounting guidance requires debt issuance costs presented direct deduction carrying amount debt balance sheet opposed presented deferred charge new guidance effective interim annual periods beginning december company debt issuance costs recorded deferred charges approximately million january fasb issued revised guidance accounting reporting financial instruments new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income new guidance also simplifies impairment testing equity investments without readily determinable fair values changes certain disclosure requirements guidance effective interim annual periods beginning early adoption permitted company currently assessing impact adoption consolidated financial statements restructuring restructuring program company initiated actions global restructuring program restructuring program part global initiative sharpen commercial research development focus actions program primarily include elimination positions sales administrative headquarters organizations well research development additionally actions include reduction companys global real estate footprint improvements efficiency manufacturing supply network company recorded total pretax costs million billion related restructuring program since inception restructuring program december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions actions restructuring program substantially completed end accordingly january remaining accrued liability future separations restructuring program combined remaining accrued liability merger restructuring program see remaining activities programs accounted aggregate prospectively merger restructuring program subsequent merck scheringplough corporation scheringplough merger company commenced actions global restructuring program merger restructuring program designed streamline cost structure combined company actions program initiated actions program primarily include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities table contents company recorded total pretax costs million million billion related restructuring program since inception merger restructuring program december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions nonfacility related restructuring actions merger restructuring program substantially complete accordingly noted january remaining accrued liability future separations restructuring program combined remaining accrued liability merger restructuring program remaining activities programs primarily relate ongoing facility rationalizations accounted aggregate prospectively company expects complete actions end incur approximately billion additional pretax costs company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested october company sold active pharmaceutical ingredient api manufacturing business including related manufacturing facility netherlands aspen holdings aspen part planned manufacturing facility rationalizations merger restructuring program connection sale aspen acquired certain branded products merck transferred aspen effective december consideration transaction included cash million notes receivable present value million time disposition cash portion consideration company received million fourth quarter remaining million received company january restructuring program merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness pretax costs million recorded related restructuring program segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated year ended december costs depreciation total restructuring program materials production marketing administrative research development restructuring costs merger restructuring program materials production marketing administrative research development restructuring costs year ended december restructuring program materials production marketing administrative research development restructuring costs merger restructuring program materials production marketing administrative research development restructuring costs year ended december restructuring program materials production marketing administrative research development restructuring costs merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production marketing administrative restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated positions eliminated restructuring program approximately positions eliminated merger restructuring program approximately position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference table contents depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather record impairment charge anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note share based compensation activity also reflects net pretax losses resulting sales facilities related assets million million million primarily reflecting loss transaction aspen discussed adjustments previously recorded amounts material period following table summarizes charges spending relating restructuring activities program separation accelerated costs depreciation total restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december merger restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december nonfacility related cash outlays associated restructuring program merger restructuring program substantially completed end remaining cash outlays expected substantially completed end acquisitions divestitures research collaborations license agreements company continues strategy establishing external alliances complement internal research capabilities including research collaborations licensing preclinical clinical compounds drive near longterm growth company supplements internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development company also reviews pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain products table contents acquisition cubist pharmaceuticals inc january merck acquired cubist leader development therapies treat serious infections caused broad range bacteria acquisition complements mercks existing hospital acute care business total consideration transferred billion includes cash paid outstanding cubist shares billion well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf cubist sharebased compensation payments settle nonvested equity awards attributable postcombination service recognized transaction expense addition company assumed outstanding convertible debt cubist fair value approximately billion acquisition date merck redeemed debt february transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date fair value assets acquired liabilities assumed cubist follows cash cash equivalents accounts receivable inventories current assets property plant equipment identifiable intangible assets products product rights year weightedaverage useful life iprd noncurrent assets current liabilities deferred income tax liabilities longterm debt noncurrent liabilities total identifiable net assets goodwill consideration transferred included current liabilities noncurrent liabilities contingent consideration million million respectively goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated pharmaceutical segment goodwill deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach fair value estimated based market participant expectations assets discounted projected net cash flows companys estimates projected net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probability adjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed significant intangible assets relate zerbaxa cubicin sivextro see note company recorded fair value incomplete research project surotomycin mk time acquisition reached technological feasibility alternative future use amount capitalized accounted indefinitelived intangible asset subject impairment testing completion abandonment project fair value surotomycin determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflects stage development project associated probability successful completion net cash flows table contents discounted present value using discount rate second quarter company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge see note connection cubist acquisition liabilities recorded potential future consideration contingent upon achievement future salesbased milestones fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows changes inputs could result different fair value measurement transaction closed january accordingly results operations acquired business included companys results operations beginning date cubist contributed sales billion mercks revenues company longer able provide results operations attributable cubist operations cubist largely integrated company incurred million transaction costs directly related acquisition cubist including sharebased compensation costs severance costs legal advisory fees reflected marketing administrative expenses following unaudited supplemental pro forma data presents consolidated information acquisition cubist completed january years ended december sales net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders unaudited supplemental pro forma data reflects historical information merck cubist adjusted include additional amortization expense based fair value assets acquired additional interest expense would incurred borrowings used fund acquisition transaction costs associated acquisition related tax effects adjustments pro forma data considered indicative results would occurred acquisition consummated january indicative future results transactions december company divested remaining ophthalmics portfolio international markets mundipharma ophthalmology products limited merck received consideration approximately million recognized gain million recorded income expense net july merck acquired ccam privately held biopharmaceutical company focused discovery development novel cancer immunotherapies acquisition provides merck ccams lead pipeline candidate cm novel monoclonal antibody targeting immune checkpoint protein ceacam evaluated phase study treatment advanced recurrent malignancies including melanoma nonsmallcell lung bladder gastric colorectal ovarian cancers total purchase consideration transaction million included upfront payment million cash future additional payments million associated attainment certain clinical development regulatory commercial milestones company determined fair value million acquisition date transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date merck recognized intangible asset iprd million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate table contents fair value contingent consideration determined utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment also utilizing discount rate actual cash flows likely different assumed transaction closed july accordingly results operations acquired business included companys results operations beginning date pro forma financial information included ccams historical financial results significant compared companys financial results also july merck allergan plc allergan entered agreement pursuant allergan acquired exclusive worldwide rights mk mk mercks investigational small molecule oral calcitonin generelated peptide cgrp receptor antagonists developed treatment prevention migraine terms agreement allergan acquired rights upfront payments million million paid august upon closing transaction million payable april merck additionally entitled receive potential development commercial milestone payments tiered doubledigit royalties based commercialization programs allergan fully responsible development cgrp programs well manufacturing commercialization upon approval launch products company recorded gain million within income expense net related transaction february merck ngm biopharmaceuticals inc ngm privately held biotechnology company entered multiyear collaboration research discover develop commercialize novel biologic therapies across wide range therapeutic areas collaboration includes multiple drug candidates currently preclinical development ngm including np evaluated treatment diabetes obesity nonalcoholic steatohepatitis ngm lead research development existing preclinical candidates autonomy identify pursue discovery stage programs discretion merck option license resulting ngm programs following human proof concept trials merck exercises option merck lead global product development commercialization resulting products approved terms agreement merck made upfront payment ngm million included research development expenses purchased equity stake ngm million merck committed million fund ngms efforts initial fiveyear term collaboration potential additional funding certain conditions met prior merck initiating phase study licensed program ngm may elect either receive milestone royalty payments certain cases cofund development participate global cost revenue share arrangement agreement also provides ngm option participate co promotion cofunded program united states merck option extend research agreement two additional twoyear terms party certain termination rights agreement event uncured material breach party additionally merck certain termination rights event occurrence certain defined conditions upon termination event depending circumstances parties varying rights obligations respect continued development commercialization compounds discovered agreement certain related payment obligations december merck acquired oncoethix privately held biotechnology company specializing oncology drug development total purchase consideration transaction million included upfront cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved company determined fair value million acquisition date transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date merck recognized intangible asset iprd million related mk formerly otx investigational novel oral bet bromodomain inhibitor currently phase studies treatment hematological malignancies advanced solid tumors well liability contingent consideration million net assets million fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate fair value contingent consideration determined utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment also utilizing discount rate actual cash flows likely different assumed transaction closed december accordingly results operations acquired business included companys results operations beginning date pro forma table contents financial information included oncoethixs historical financial results significant compared companys financial results october company completed sale merck consumer care mcc business bayer ag bayer billion billion net cash divested less customary closing adjustments well certain contingent amounts held back payable upon manufacturing site transfer canada regulatory approval korea terms agreement bayer acquired mercks existing overthecounter business including global trademark prescription rights claritin afrin company recognized pretax gain sale mcc billion also october company entered worldwide clinical development collaboration bayer market develop portfolio soluble guanylate cyclase sgc modulators includes bayers adempas riociguat first member novel class compounds adempas approved treat pulmonary arterial hypertension pah approved patients chronic thromboembolic pulmonary hypertension cteph adempas marketed united states europe pah cteph japan cteph two companies equally share costs profits collaboration implement joint development commercialization strategy collaboration also includes clinical development bayers vericiguat currently phase trials worsening heart failure well optin rights earlystage sgc compounds development bayer merck turn make available early stage sgc compounds similar terms return broad collaboration rights merck made upfront payment bayer billion potential additional milestone payments billion upon achievement agreedupon sales goals adempas bayer continue lead commercialization americas merck lead commercialization rest world vericiguat potential optin products bayer lead rest world merck lead americas products candidates included agreement companies share development costs profits sales right copromote territories lead company determined mercks payment access bayers compounds constituted acquisition asset billion consideration paid merck million fair value related adempas capitalized intangible asset subject amortization estimated useful life years remaining million fair value related vericiguat compound clinical development expensed within research development expenses fair values adempas vericiguat determined using income approach fair value estimated based upon probabilityadjusted future net cash flows vericiguat also stage development project associated probability successful completion net cash flows discounted present value using discount rate adempas vericiguat future sales based milestones accrued probable achieved related intangible asset recognized amortized materials production costs applicable useful life company bayer right terminate agreement cause productbyproduct basis products developed commercialized agreement adempas bayer termination rights event partys material uncured breach related product september merck sun pharmaceutical industries ltd sun pharma entered exclusive worldwide licensing agreement mercks investigational therapeutic antibody candidate mk tildrakizumab treatment chronic plaque psoriasis skin ailment terms agreement sun pharma acquired worldwide rights tildrakizumab use human indications merck exchange upfront payment million merck continue clinical development regulatory activities funded sun pharma upon product approval sun pharma responsible regulatory activities including subsequent submissions pharmacovigilance post approval studies manufacturing commercialization approved product merck also eligible receive future payments associated regulatory including product approval sales milestones well tiered royalties ranging midsingle digit teen percentage rates sales merck recorded loss million transaction included income expense net august merck completed acquisition idenix pharmaceuticals inc idenix approximately billion cash billion net cash acquired idenix biopharmaceutical company engaged discovery development medicines treatment human viral diseases whose primary focus development nextgeneration oral antiviral therapeutics treat hepatitis c virus hcv infection transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date merck recognized intangible asset iprd billion related table contents mk formerly idx net deferred tax liabilities million net liabilities million mk nucleotide prodrug phase clinical development evaluated potential inclusion development oral pangenotypic fixeddose combination regimens excess consideration transferred fair value net assets acquired billion recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate actual cash flows likely different assumed transaction closed august accordingly results operations acquired business included companys results operations beginning date pro forma financial information included idenixs historical financial results significant compared companys financial results may merck entered agreement sell certain ophthalmic products santen pharmaceutical co ltd santen japan markets europe asia pacific agreement provided upfront payments santen additional payments based defined sales milestones santen also purchase supply ophthalmology products covered agreement two fiveyear period transaction closed markets july remaining markets october company received million upfront payments santen net certain adjustments recognized gains million transactions included income expense net march merck divested sirna therapeutics inc sirna subsidiary alnylam pharmaceuticals inc alnylam consideration million shares alnylam common stock merck eligible receive future payments associated achievement certain regulatory commercial milestones well royalties future sales merck recorded gain million income expense net related transaction excess mercks tax basis investment sirna value received resulted approximate million tax benefit recorded january merck sold us marketing rights saphris antipsychotic indicated treatment schizophrenia bipolar disorder adults forest laboratories inc forest terms agreement forest made upfront payments million recorded sales make additional payments merck based defined sales milestones addition part transaction merck agreed supply product forest subsequently acquired allergan patent expiry february merck supera farma laboratorios sa supera brazilian pharmaceutical company coowned cristlia eurofarma established joint venture markets distributes sells portfolio pharmaceutical branded generic products merck cristlia eurofarma brazil merck owns joint venture cristlia eurofarma collectively transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values resulted merck recognizing intangible assets currently marketed products million iprd million goodwill million deferred tax liabilities million company also recorded increases noncontrolling interests paidin capital amounts million million respectively transaction closed february accordingly results operations acquired business included companys results operations beginning date company recorded certain intangible asset impairments charges related supera joint venture see note remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis auto injector delivery system european commission approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial table contents sale simponi european union eu following receipt pricing reimbursement approval within eu remicade lost market exclusivity major european markets february company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates primary objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premiums writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows table contents fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes primary objective balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci included cumulative translation adjustment pretax gains million million pretax losses million eurodenominated notes interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table table contents number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts noncurrentother assets interest rate swap contracts current accrued current liabilities interest rate swap contracts noncurrentother noncurrent liabilities foreign exchange contracts current current assets foreign exchange contracts noncurrent assets foreign exchange contracts current accrued current liabilities derivatives designated hedging instruments foreign exchange contracts current current assets foreign exchange contracts noncurrent assets foreign exchange contracts current accrued current liabilities foreign exchange contracts noncurrent noncurrent liabilities table contents noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amount subject offset master netting arrangements offset consolidated balance sheet cash collateral received posted net amounts table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated foreign currency cash flow hedging relationship iii designated foreign currency net investment hedging relationship iv designated hedging relationship years ended december derivatives designated fair value hedging relationship interest rate swap contracts amount gain loss recognized income expense net derivatives amount loss gain recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount gain loss reclassified aoci sales amount gain recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount gain recognized oci derivatives derivatives designated hedging relationship foreign exchange contracts amount gain loss recognized income expense net derivatives amount gain loss recognized sales million million million ineffectiveness hedge respectively ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information availableforsale investments december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds commercial paper us government agency securities assetbacked securities mortgagebacked securities foreign government bonds equity securities availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds commercial paper us government agency securities assetbacked securities mortgagebacked securities foreign government bonds equity securities assets securities held employee compensation derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts written currency options interest rate swaps total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant transfers level level december cash cash equivalents billion included billion cash equivalents considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration follows fair value january changes fair value additions payments fair value december recorded research development expenses materials production costs company recognized liabilities contingent consideration million related acquisition cubist million related acquisition ccam see note addition company paid million contingent consideration related first commercial sale zerbaxa united states fair value liability contingent consideration related acquisition occurred increased million resulting progression program preclinical phase increase resulted higher fair value future regulatory milestone royalty payments due increased probability success program given progression phase addition company recognized liability million contingent consideration related acquisition oncoethix see note fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor economic conditions including volatility associated international sovereign economies associated impacts financial markets business taking consideration global economic conditions ongoing sovereign debt issues certain european countries december assets included million million respectively accounts receivable expected collected within one year december companys total net accounts receivable outstanding one year approximately million company expect writeoffs adjustments accounts receivable would material adverse effect financial position liquidity results operations companys customers largest accounts receivable balances amerisourcebergen corporation cardinal health inc mckesson corporation zuellig pharma ltd asia pacific aah pharmaceuticals ltd uk represented aggregate approximately onethird total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales table contents derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december company received cash collateral million billion respectively various counterparties obligation return collateral recorded accrued current liabilities company advanced cash collateral counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost increase lifo costs recognized inventories assets inventories valued lifo method comprised approximately billion billion inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical total balance january acquisitions divestitures impairments balance december acquisitions divestitures impairments balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses december million million respectively additions goodwill pharmaceutical segment resulted primarily acquisition cubist see note reductions pharmaceutical segment goodwill resulted divestiture companys remaining ophthalmics business international markets see note impairments goodwill within nonreportable segments relates primarily certain businesses within healthcare services segment table contents additions goodwill pharmaceutical segment primarily resulted acquisition idenix reductions resulted sale mcc divestiture certain ophthalmic products several international markets see note reductions goodwill segments resulted termination companys relationship astrazeneca lp azlp see note divestiture mcc also third quarter company recorded impairment charge goodwill related supera joint venture result changes cash flow assumptions certain compounds currently marketed products intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights inprocess research development tradenames acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives increase intangible assets products product rights primarily relates acquisition cubist see note companys significant acquired intangibles related marketed products included product product rights december include zerbaxa billion zetia billion vytorin billion sivextro billion implanonnexplanon million dificid million nuvaring million nasonex million cubicin million company recognized intangible asset related adempas result formation collaboration bayer see note carrying value million december reflected table company recorded impairment charges related marketed products intangibles million billion million respectively within material production costs charges primarily relate impairment customer relationship tradename intangibles certain businesses within healthcare services segment amount recorded million related pegintron million related victrelis million related rebetol products marketed company treatment chronic hcv infection sales products adversely affected loss market share patient treatment delays markets anticipating availability newer therapeutic options trends accelerated rapidly previously anticipated company addition developments competitive hcv treatment market led market share losses greater company predicted factors caused changes cash flow projections pegintron victrelis rebetol indicated intangible asset values recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair values intangible assets related pegintron victrelis rebetol compared related carrying values resulted impairment charges noted impairment charges recorded million resulted lower cash flow projections saphrissycrest due reduced expectations international markets united states revisions cash flows indicated saphrissycrest intangible asset value recoverable undiscounted cash flows basis company utilized market participant assumptions considered several different scenarios determine best estimate fair value intangible asset related saphrissycrest compared related carrying value resulted impairment charge noted remaining million impairment charges resulted lower cash flow projections rebetol due reduced expectations japan europe revisions cash flows indicated rebetol intangible asset value recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related rebetol compared related carrying value resulted impairment charge noted iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts table contents capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life assets begin amortization million million million respectively iprd reclassified products product rights upon receipt marketing approval major market company recorded million iprd impairment charges within research development expenses amount million relates surotomycin clinical development program obtained connection acquisition cubist company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted company recorded million iprd impairment charges primarily result changes cash flow assumptions certain compounds obtained connection supera joint venture well discontinuation certain animal health programs company recorded million iprd impairment charges amount million related writeoff intangible asset associated preladenant result discontinuation clinical development program compound addition company recorded impairment charges resulting changes cash flow assumptions certain compounds well pipeline programs previously deprioritized subsequently deemed alternative use period iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within materials production costs billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates including sanofi pasteur msd certain investments funds well azlp termination companys relationship azlp june discussed equity income affiliates million million million included income expense net see note investments affiliates accounted using equity method including joint ventures totaled million december million december amounts reported assets amounts due joint ventures included current assets million december million december astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange table contents general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights merck earned revenue based sales kbi products revenue million million primarily relating sales nexium well prilosec addition merck earned certain partnership returns azlp million million recorded equity income affiliates june astrazeneca exercised option purchase mercks interest kbi million cash amount million reflects estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june deferred recognized time income expense net contingency eliminated sales occur million million respectively deferred income recognized bringing cumulative deferred income recognized december million remaining exercise price million primarily represents multiple ten times mercks average annual profit allocation partnership three years prior exercise merck recognized million gain within income expense net result astrazenecas option exercise companys remaining interest azlp redeemed accordingly company also recognized noncash gain approximately million within income expense net resulting retirement billion kbi preferred stock see note elimination companys billion investment azlp million reduction goodwill transaction resulted net tax benefit million primarily reflecting reversal deferred taxes azlp investment balance result astrazeneca exercising option july company longer records equity income azlp supply sales azlp terminated summarized financial information azlp follows years ended december sales materials production costs expense net income taxes includes results june termination date mercks partnership returns azlp generally contractually determined noted based percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales million billion billion loans payable longterm debt commitments loans payable december included billion notes due million shortterm foreign borrowings million longdated notes subject repayment option holder loans payable december included billion notes due billion commercial paper million shortterm foreign borrowings million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due notes due floatingrate borrowing due notes due notes due notes due floatingrate notes due notes due eurodenominated notes due notes due notes due notes due debentures due debentures due floatingrate notes due debentures due notes due notes due floatingrate borrowing due presented table included million million december respectively borrowings variable rates resulted effective interest rates zero also included foreign borrowings million million december respectively varying rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices february merck issued billion aggregate principal amount senior unsecured notes consisting million principal amount floating rate notes due million principal amount floating rate notes due billion principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due company used portion net proceeds offering billion repay commercial paper issued substantially finance companys acquisition cubist remaining net proceeds used general corporate purposes including repurchases companys common stock repayment outstanding commercial paper borrowings debt maturities also february company redeemed billion legacy cubist debt acquired acquisition see note table contents october company issued billion principal amount senior unsecured notes net proceeds offering billion used part repay debt validly tendered connection tender offers launched company certain outstanding notes debentures company paid billion aggregate consideration applicable purchase price together accrued interest redeem billion principal amount debt november merck redeemed additional billion principal amount senior unsecured notes company recorded pretax loss million connection transactions effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply financial covenants including requirement total debt capitalization ratio defined applicable agreements exceed december company compliance covenants aggregate maturities longterm debt next five years follows billion million billion billion billion august company terminated existing credit facility entered billion fiveyear credit facility matures august facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including environmental matters opinion company unlikely resolution matters material companys financial position results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities effective august table contents vioxx litigation product liability lawsuits previously disclosed merck defendant approximately active federal state lawsuits vioxx product liability lawsuits alleging personal injury result use vioxx cases coordinated multidistrict litigation us district court eastern district louisiana vioxx mdl judge eldon e fallon previously disclosed merck also defendant approximately putative class action lawsuits alleging economic injury result purchase vioxx one cases vioxx mdl merck reached resolution approved judge fallon class actions vioxx mdl settlement merck pay million resolve properly documented claims submitted class members approved attorneys fees expenses approved settlement notice costs certain administrative expenses court entered order approving settlement january claims review process recently completed merck also defendant lawsuits brought state attorneys general three states alaska montana utah lawsuits pending state courts actions allege merck misrepresented safety vioxx seek recovery expenditures vioxx governmentfunded health care programs medicaid andor penalties alleged consumer fraud act violations trial scheduled montana case september trial set alaska case january motions judgment pleadings alaska montana cases currently pending motion dismiss recently filed utah case shareholder lawsuits previously disclosed addition vioxx product liability lawsuits various putative class actions individual lawsuits filed merck certain former employees alleging defendants violated federal securities laws making alleged material misstatements omissions respect cardiovascular safety vioxx vioxx securities lawsuits vioxx securities lawsuits coordinated multidistrict litigation us district court district new jersey judge stanley r chesler consolidated purposes august judge chesler granted part denied part mercks motion dismiss fifth amended class action complaint consolidated securities class action among things court dismissed certain defendants case also dismissed claims based statements made voluntary withdrawal vioxx september october remaining defendants answered fifth amended class action complaint april plaintiffs filed motion class certification period may september court granted january march plaintiffs filed motion leave amend complaint add certain allegations expand class period may court denied plaintiffs motion leave amend complaint expand class period granted plaintiffs leave amend complaint add certain allegations within existing class period june plaintiffs filed sixth amended class action complaint class action july defendants answered class action discovery completed closed may court granted part denied part defendants motions summary judgment court granted judgment defendants favor five alleged misstatements including statements prior march denied motion respect remaining statements january company announced reached agreement plaintiffs settle class action million plus additional amount attorneys fees expenses exchange among things dismissal prejudice class action full releases claims defendants available funds certain insurance policies mercks net cash payment settlement fees approximately million proposed settlement covers claims relating vioxx settlement class members purchased merck securities may october settlement admission wrongdoing part settlement agreement defendants continue deny allegations proposed settlement including award attorneys fees expenses subject final court approval february parties filed stipulation settlement court preliminarily approved february court set final approval hearing june proposed settlement resolve individual securities lawsuits discussed previously disclosed individual securities lawsuits filed foreign domestic institutional investors also consolidated vioxx securities lawsuits allegations individual securities lawsuits substantially similar allegations vioxx securities lawsuits discovery completed actions proposed settlement class action discussed resolve individual securities lawsuits table contents although individual plaintiff right option join settlement class additional cost merck light proposed settlement class action court adjourned previouslyscheduled trial date march cases consolidated action court scheduled conference february discuss pretrial schedule parties individual lawsuits settlement reached insurance result previously disclosed insurance arbitration company receive insurance proceeds approximately million connection settlement class action company also directors officers insurance coverage applicable vioxx securities lawsuits remaining stated upper limits approximately million disputes insurers availability companys directors officers insurance coverage claims amounts actually recovered directors officers policies discussed paragraph may less stated upper limits international lawsuits previously disclosed addition lawsuits discussed merck named defendant litigation relating vioxx brazil europe collectively vioxx international lawsuits previously disclosed january company entered agreement resolve claims related vioxx canada april company paid approximately million settlement fund agreement approved courts canadas provinces december claims administrator finalized claimant eligibility determinations company made final payment approximately million settlement fund reserves connection settlement class action remains subject final court approval company established net reserve million fourth quarter company believes meritorious defenses remaining vioxx product liability lawsuits vioxx securities lawsuits vioxx international lawsuits collectively remaining vioxx litigation vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect remaining vioxx litigation company established reserve respect certain vioxx product liability lawsuits company also immaterial remaining reserve relating previously disclosed vioxx investigation nonparticipating states litigation continuing company established liability reserves respect remaining vioxx litigation product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases filed pending merck either federal state court including one case seeks class action certification well damages andor medical monitoring approximately actions plaintiffs allege among things suffered osteonecrosis jaw onj generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax however large majority actions subject settlement discussed addition plaintiffs approximately actions generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax cases alleging onj andor jaw related injuries august judicial panel multidistrict litigation jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax onj mdl coordinated pretrial proceedings december merck reached agreement principle plaintiffs steering committee psc fosamax onj mdl resolve pending onj cases appeal fosamax onj mdl state table contents courts aggregate amount million merck psc subsequently formalized terms agreement master settlement agreement onj master settlement agreement executed april condition settlement state federal onj plaintiffs agree participate settlement plan merck could either terminate onj master settlement agreement waive participation requirement agree lesser funding amount settlement fund july merck elected proceed onj master settlement agreement reduced funding level since participation level approximately merck fully funded onj master settlement agreement escrow agent agreement begun making settlement payments qualifying plaintiffs approximately nonparticipants cases remain settlement complete onj master settlement agreement effect cases alleging femur fractures discussed cases alleging femur fractures march merck submitted motion transfer jpml seeking federal cases alleging femur fractures consolidated one multidistrict litigation coordinated pretrial proceedings motion transfer granted may federal cases involving allegations femur fracture transferred multidistrict litigation district new jersey femur fracture mdl judge pisano presided femur fracture mdl march time femur fracture mdl reassigned judge pisano judge freda l wolfson following judge pisanos retirement bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealing decision us court appeals third circuit june femur fracture mdl court dismissed without prejudice another approximately cases pending plaintiffs appeal preemption ruling third circuit june judge pisano granted merck summary judgment gaynor v merck case found mercks updates january fosamax label regarding atypical femur fractures adequate matter law merck adequately communicated changes plaintiffs gaynor appealed judge pisanos decision third circuit august merck filed motion requesting judge pisano enter order requiring plaintiffs femur fracture mdl claim fosamax label inadequate proximate cause alleged injuries show cause cases dismissed based courts preemption decision ruling gaynor case november court granted mercks motion entered requested show cause order december approximately cases pending femur fracture mdl excluding cases dismissed prejudice preemption grounds pending appeal cases dismissed without prejudice also pending aforementioned appeal december approximately cases alleging femur fractures filed new jersey state court pending judge jessica mayer middlesex county parties selected initial group cases reviewed fact discovery two additional groups cases reviewed fact discovery selected november march respectively group cases reviewed fact discovery selected merck july december approximately cases alleging femur fractures filed pending california state court petition filed seeking coordinate femur fracture cases filed california state court single judge orange county california petition granted judge thierry colaw currently presiding coordinated proceedings march court directed group discovery pool cases reviewed fact discovery subsequently scheduled galper v merck case plaintiffs selected first trial galper trial began february jury returned verdict mercks favor april plaintiff appealed verdict california appellate court next femur fracture trial california scheduled held april currently set include several plaintiffs table contents additionally six femur fracture cases pending state courts discovery ongoing femur fracture mdl state courts femur fracture cases pending company intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december approximately product user claims served merck alleging generally use januvia andor janumet caused development pancreatic cancer injuries complaints filed several different state federal courts claims filed consolidated multidistrict litigation proceeding us district court southern district california called incretinbased therapies products liability litigation mdl mdl includes federal lawsuits alleging pancreatic cancer due use following medicines januvia janumet byetta victoza latter two products manufactured pharmaceutical companies majority claims filed mdl filed superior court california county los angeles california state court cases pending merck state courts california state court november mdl granted summary judgment grounds preemption claims alleging injury due pancreatic cancer based ruling november mdl entered final judgment resulting dismissal pancreatic cancer claims merck relating approximately product users november california state court likewise granted summary judgment preemption grounds claims alleging injury due pancreatic cancer result dismissal pancreatic cancer claims merck relating approximately product users plaintiffs appealing mdl preemption ruling expected likewise respect california state court ruling court enters final judgment addition claims noted company agreed december toll statute limitations approximately additional claims company intends continue defending lawsuits nuvaring previously disclosed beginning may number product liability complaints filed various jurisdictions asserting claims company subsidiaries relating nuvaring combined hormonal contraceptive vaginal ring plaintiffs contended company among things failed adequately design manufacture nuvaring failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs sought damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases pending federal multidistrict litigation venued missouri pursuant settlement agreement merck negotiating plaintiffs counsel became effective june merck paid lump total settlement million resolve cases filed retainer counsel february plaintiffs approximately cases joined settlement program filed case dismissed prejudice settlement administration process completed dismissals began second quarter continued rolling basis throughout company certain insurance coverage available currently used partially fund companys legal fees insurance coverage also used fund settlement december cases pending outside settlement program inclusive cases filed settlement program closed cases pending multidistrict litigation subject individual case management orders requiring plaintiffs meet various discovery evidentiary requirements december plaintiffs meeting requirements continuing prosecute cases propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar december approximately lawsuits filed plaintiffs allege experienced persistent sexual side effects following cessation treatment propecia andor table contents proscar approximately plaintiffs also allege propecia proscar caused cause prostate cancer testicular cancer male breast cancer lawsuits filed various federal courts state court new jersey federal lawsuits consolidated pretrial purposes federal multidistrict litigation judge john gleeson eastern district new york matters pending state court new jersey consolidated judge jessica mayer middlesex county addition one matter pending state court massachusetts one matter pending state court new york company intends defend lawsuits governmental proceedings previously disclosed company received subpoena office inspector general us department health human services behalf us attorneys office district maryland civil division us department justice doj requests information relating companys marketing singulair dulera inhalation aerosol certain marketing activities january present company cooperating government previously disclosed company received civil investigative demand us attorneys office eastern district pennsylvania requests information relating companys contracting pricing dulera inhalation aerosol certain pharmacy benefit managers medicare part plans company cooperating investigation previously disclosed company received letters doj sec seek information activities number countries reference foreign corrupt practices act company cooperated agencies requests believes inquiry part broader review pharmaceutical industry practices foreign countries previously disclosed company advised doj based information received closed inquiry matter relates company future company may receive additional requests information either doj sec previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate commercial litigation kdur antitrust litigation previously disclosed june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications andas following commencement administrative proceeding us federal trade commission ftc alleging anticompetitive effects settlements resolved scheringploughs favor putative class nonclass action suits filed behalf direct indirect purchasers kdur scheringplough upshersmith lederle consolidated multidistrict litigation us district court district new jersey suits claimed violations federal state antitrust laws well state statutory common law causes action sought unspecified damages april indirect purchasers voluntarily dismissed case march district court granted summary judgment defendants remaining lawsuits dismissed matter entirety july third circuit court appeals reversed district courts grant summary judgment remanded case proceedings time third circuit upheld december decision district court certifying certain direct purchaser plaintiffs claims class action august company filed petition certiorari us supreme court seeking review third circuits decision june supreme court granted petition vacated judgment third circuit remanded case consideration light decision ftc v actavis inc decision held whether socalled reverse payment ie payment holder pharmaceutical patent party challenging patent made connection settlement dispute violates antitrust laws table contents determined basis rule reason analysis september third circuit returned case district court proceedings accordance actavis standard april company filed motions summary judgment february district court denied companys motion summary judgment relating direct purchasers claims concerning settlement upshersmith granted companys motion summary judgment relating direct purchasers claims concerning settlement lederle trial date yet set sales force litigation previously disclosed may ms kelli smith filed complaint company united states district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws november company filed motion dismiss class claims plaintiffs sought granted leave file amended complaint january plaintiffs filed amended complaint adding four additional named plaintiffs october court denied companys motion dismiss strike class claims premature september plaintiffs filed additional motions including motion conditional certification equal pay act motion amend pleadings seeking add erisa constructive discharge claims company subsidiary named defendant motion equitable relief merck filed papers opposition motions currently pending court qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery company intends defend lawsuits merck kgaa litigation january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france united kingdom uk germany alleging breach parties coexistence agreement unfair competition andor trademark infringement december paris court first instance issued judgment finding certain activities company directed towards france constitute trademark infringement unfair competition activities found infringe date kgaa taken steps appeal decision january uk high court issued judgment finding company breached coexistence agreement infringed kgaas trademark rights result certain activities directed towards uk based use word merck promotional information activity noted uk decision finding based companys use sign merck connection sale products material pharmaceutical business transacted uk decision reflects one step litigation process taking place number countries appealed patent litigation time time generic manufacturers pharmaceutical products file andas us food drug administration fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company products marketed via agreements companies currently involved patent infringement litigation united states include cancidas cubicin table contents emend injection invanz nasonex noxafil nuvaring similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges cancidas february patent infringement lawsuit filed united states xellia pharmaceuticals aps xellia respect xellias application fda seeking prepatent expiry approval market generic version cancidas june district court found xellia infringed companys patent ordered xellias application approved patent expires september including pediatric exclusivity xellia appealed decision appeal heard march august patent infringement lawsuit filed united states fresenius kabi usa llc fresenius respect freseniuss application fda seeking prepatent expiry approval market generic version cancidas lawsuit automatically stays fda approval freseniuss application december adverse court decision whichever may occur earlier cubicin march patent infringement lawsuit filed united states hospira inc hospira respect hospiras application fda seeking prepatent expiry approval market generic version cubicin trial held february december district court found composition patent expires june valid infringed later patents expiring september november found invalid hospira appealed finding composition patent invalid company crossappealed finding later patents invalid november us court appeals federal circuit affirmed lower court decision hospiras application approved least june october patent infringement lawsuit filed united states strides inc agila specialties private limited stridesagila respect stridesagilas application fda seeking prepatent expiry approval market generic version cubicin result hospira decision stridesagilas application approved least june july patent infringement lawsuit filed united states fresenius respect freseniuss application fda seeking prepatent expiry approval market generic version cubicin result hospira decision freseniuss application approved least june december patent infringement lawsuit filed united states sagent pharmaceuticals inc sagent respect sagents application fda seeking prepatent expiry approval market generic version cubicin result hospira decision sagents application approved least june december patent infringement lawsuit filed united states actavis llc actavis respect actaviss application fda seeking prepatent expiry approval market generic version cubicin result hospira decision actaviss application approved least june january patent infringement lawsuit filed united states dr reddys laboratories ltd dr reddys laboratories inc dr reddy respect dr reddys application fda seeking prepatent expiry approval market generic version cubicin result hospira decision dr reddys application approved least june earlier district court action teva parenteral medicines inc teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva resulted settlement whereby teva launch generic version cubicin latest december earlier certain conditions event june october agila specialties inc mylan pharmaceuticals inc agilamylan filed petitions inter partes review ipr united states patent trademark office uspto seeking invalidity september november patents april agilamylan withdrew petitions ipr exchange company agreeing narrow issues stridesagila lawsuit referenced november fresenius filed petitions ipr uspto seeking invalidity september patents may table contents uspto granted freseniuss petition ipr september patents ipr hearing held february july fresenius filed petitions ipr seeking invalidity november patents january uspto granted freseniuss petition ipr november patents emend injection may patent infringement lawsuit filed united states sandoz inc sandoz respect sandozs application fda seeking prepatent expiry approval market generic version emend injection trial lawsuit sandoz held august court found companys patent infringed invalid court ordered sandozs application approved expiration companys patent december sandoz dropped appeal courts decision june patent infringement lawsuit filed united states accord healthcare inc us accord healthcare inc intas pharmaceuticals ltd collectively intas respect intass application fda seeking prepatent expiry approval market generic version emend injection company agreed intas stay lawsuit outcome lawsuit sandoz october following sandoz decision court found companys patent infringed invalid court ordered intass application approved expiration companys patent july patent infringement lawsuit filed united states fresenius respect freseniuss application fda seeking prepatent expiry approval market generic version emend injection january parties settled matter terms settlement fresenius entitled enter market prepatent expiry except certain conditions december apotex inc apotex filed petition ipr uspto seeking invalidity claims compound patent covering emend injection uspto rejected apotexs petition june invanz july patent infringement lawsuit filed united states hospira respect hospiras application fda seeking prepatent expiry approval market generic version invanz lawsuit automatically stays fda approval hospiras application november adverse court decision whichever may occur earlier since hospira challenge earlier patent covering invanz application fda approved least patent expires may trial matter scheduled begin april august patent infringement lawsuit filed united states savior lifetec corporation savior respect saviors application fda seeking prepatent expiry approval market generic version invanz lawsuit automatically stays fda approval saviors application november adverse court decision whichever may occur earlier since savior challenge earlier patent covering invanz application fda approved least patent expires may nasonex july patent infringement lawsuit filed united states teva pharmaceuticals usa inc teva pharma respect teva pharmas application fda seeking prepatent expiry approval market generic version nasonex lawsuit automatically stays fda approval teva pharmas application november adverse court decision whichever may occur earlier trial matter scheduled begin may march patent infringement lawsuit filed united states amneal pharmaceuticals llc amneal respect amneals application fda seeking prepatent expiry approval market generic version nasonex lawsuit automatically stays fda approval amneals application august adverse court decision whichever may occur earlier trial matter scheduled begin june previous decision issued june held merck patent teva pharma amneal lawsuits covering mometasone furoate monohydrate valid infringed apotex corps proposed product april patent infringement lawsuit filed apotex inc apotex corp apotex respect apotexs application fda seeking prepatent expiry approval market generic version nasonex allegedly differs generic version previous lawsuit noxafil august company filed lawsuit actavis laboratories fl inc actavis united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil lawsuit automatically stays fda approval actaviss application december adverse court decision whichever may occur earlier nuvaring december company filed lawsuit subsidiary allergan united states respect companys application fda seeking prepatent expiry approval sell generic version table contents nuvaring trial matter held january company awaiting courts decision september company filed lawsuit teva pharma united states respect companys application fda seeking prepatent expiry approval sell generic version nuvaring antipd antibody patent oppositions litigation previously disclosed ono pharmaceutical co ono european patent ep broadly claims use antipd antibody companys immunotherapy keytruda treatment cancer ono previously licensed commercial rights antipd antibody bristol myers squibb bms certain markets company believes patent invalid filed opposition european patent office epo seeking revocation june opposition division epo found claims patent valid company received opposition divisions written opinion september company submitted substantive appeal february april company three companies opposed another european patent ep owned bms ono believes invalid patent valid broadly claims antipd antibodies could include keytruda bms ono recently submitted request amend claims patent epo allows amendment claims patent would longer broadly claim antipd antibodies keytruda may company filed lawsuit uk seeking revocation uk national versions patents july ono bms sued company seeking declaration patent would infringed uk marketing keytruda company sought declaration uk court keytruda infringe patent uk bms ono notified company request amend claims epo patent intention seek permission court similarly amend uk national version claims patent would longer broadly claim antipd antibodies keytruda trial held uk july trial issues validity infringement patent heard time court october court issued judgment finding patent valid infringed merck appealed judgment february company filed lawsuits netherlands seeking revocation dutch national versions patents bms ono amended claims patent claims patent longer broadly claim antipd antibodies keytruda trial regarding validity infringement patent held january company anticipating decision april december bms ono filed lawsuits company france ireland switzerland germany alleging infringement patent january bms ono filed lawsuit company spain alleging infringement patent france bms ono filed preliminary relief seeking payment damages france case pending hearing preliminary relief set february dates trials regarding validity infringement irish french swiss spanish national versions patent yet scheduled trial concerning infringement german version patent currently scheduled begin march company continues believe patent invalid company file lawsuits seeking revocation patents national courts europe time ono bms file patent infringement actions company national courts europe around time company launches keytruda national court determines company infringed valid claim patent ono bms may entitled monetary damages including royalties future sales keytruda potentially could seek injunction prevent company marketing keytruda country uspto granted us patent nos ono ono bms patents equivalent patents respectively september bms ono filed lawsuit united states alleging marketing keytruda company infringe us patent bms ono seeking prevent stop marketing keytruda united states trial matter currently scheduled begin april company believes patent patent invalid recently ono filed lawsuits united states alleging marketing keytruda company table contents infringe us patent nos patents related patent company believes patents also invalid september company filed lawsuit australia seeking revocation australian patent equivalent patent march bms ono counterclaimed matter alleging companys manufacture supply keytruda australian market infringe australian patent ono bms similar patents applications company closely monitoring pending united states japan countries company confident able market keytruda country approved prevented ono bms patents pending applications litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters previously disclosed mercks facilities oss netherlands inspected province brabant province pursuant dutch hazards major accidents decree sites environmental permits province issued penalties alleged violations regulations governing preventing managing accidents hazardous substances government also issued fine alleged environmental violations one oss facilities together totaled thousand company subsequently advised criminal investigation initiated based upon certain issues formed basis administrative enforcement action province company intends defend enforcement action may result investigation may environmental protection agency conducted air compliance evaluation companys pharmaceutical manufacturing facility elkton virginia result investigation company recently issued notice noncompliance show cause notification relating certain federally enforceable requirements applicable elkton facility company attempting resolve alleged violations way settlement defend settlement reached company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government table contents cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans noncontrolling interests connection restructuring ami merck assumed billion par value preferred stock dividend rate per annum carried kbi included noncontrolling interests astrazeneca exercised option acquire mercks interest azlp see note preferred stock obligation retired sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees company also issues rsus employees certain companys equity method investees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled primarily treasury shares table contents employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus certain psus granted december employees participate dividends basis common shares dividends nonforfeitable holder rsus psus issued january dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december table contents additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries beginning january active participants mercks primary us defined benefit pension plans accruing pension benefits using cash balance formulas based age service pay interest however transition period january december participants earn greater benefit calculated employees legacy final average pay formula cash balance formula years service december participants earn future benefits cash balance formula addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net periodic benefit cost credit changes net periodic benefit cost pension postretirement benefit plans year year largely attributable changes discount rate affecting net amortization table contents connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans addition settlements recorded certain us international pension plans obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial gains losses benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans actuarial gains reflect change discount rate actuarial losses reflect change discount rate us plans also reflect impact companys adoption new retirement plan mortality assumptions issued society actuaries october decline benefit obligation postretirement benefits resulting plan amendments primarily reflects changes mercks retiree medical benefits approved company december changes provide beginning merck provide access retiree health insurance coverage supplements governmentsponsored medicare private insurance marketplace new approach allow medicareeligible retirees choose insurance terms cost coverage best fits needs still receiving financial support determined merck companys subsidy retirees medical coverage table contents expected comparable future changes support based number factors business conditions government actions marketplace changes general consumer inflation rate information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments year end categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total us pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations fixed income obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments derivatives liabilities derivatives international pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts plans level investments real estate funds generally valued market appraisals underlying investments funds plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales balance december international pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations fixed income obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments derivatives table contents company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net gain loss arising period prior service cost credit arising period net loss amortization included benefit cost prior service credit cost amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension table contents plans million million respectively relates us pension plans estimated prior service cost credit amounts amortized aoci net pension postretirement benefit cost postretirement benefit plans million actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis developing expected rate return within plan longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return range range us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses equity income affiliates net increase exchange losses driven venezuela second quarter upon evaluation evolving economic conditions venezuela volatility country company determined unlikely outstanding net monetary assets would settled official rate vef bolvar fuertes per us dollar accordingly second quarter company recorded charge million devalue net monetary assets venezuela amount included companys estimate us dollar amount would ultimately collected third quarter company recorded additional exchange losses million aggregate reflecting ongoing effect translating transactions net monetary assets consistent second quarter fourth quarter result deterioration economic conditions venezuela continued declines transactions settled official rate company began using simadi rate report venezuelan operations company also revalued remaining net monetary assets simadi rate resulted additional charge fourth quarter million exchange losses reflect million losses due venezuelan currency devaluation february venezuelan government devalued currency vef per us dollar vef per us dollar company recognized losses due exchange approximately million resulting remeasurement local monetary assets liabilities new rate since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations decline equity income affiliates compared driven primarily termination companys relationship azlp june see note lower equity income azlp partially offset higher equity income certain research investment funds net presented table includes million net charge related settlement vioxx shareholder class action litigation see note expense million contribution investments equity securities merck foundation partially offset million gain sale certain migraine clinical development programs see note million gain divestiture mercks remaining ophthalmics business international markets see note recognition million deferred income related astrazenecas option exercise see note net includes billion gain divestiture mcc see note gain million related astrazenecas option exercise see note million gain divestiture certain ophthalmic products several international markets see note gain million related divestiture sirna see note recognition million deferred income related astrazenecas option exercise partially offset million loss extinguishment debt see note million goodwill impairment charge related companys joint venture supera see note interest paid million million million table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings tax settlements astrazeneca option exercise sale sirna therapeutics inc american taxpayer relief act impact purchase accounting adjustments including amortization foreign currency devaluation related venezuela unremitted foreign earnings restructuring state taxes us health care reform legislation divestiture merck consumer care includes tax effect contingency reserves research credits tax rate changes miscellaneous items foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate companys effective tax rate reflects impact protecting americans tax hikes act signed law december extending research credit permanently controlled foreign corporation lookthrough provisions five years companys effective tax rate reflects impact tax increase prevention act signed law december extending research credit controlled foreign corporation lookthrough provisions one year american taxpayer relief act signed law january extending research credit controlled foreign corporation lookthrough provisions two years retroactively january december company recorded entire benefit million financial statement period included date enactment income taxes consisted years ended december domestic foreign table contents taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes discussed note company elected retrospectively early adopt new accounting guidance requires deferred tax assets liabilities along related valuation allowance classified noncurrent balance sheet adoption standard following impact consolidated balance sheet amounts previously reported current assets reduced million assets increased million accrued current liabilities reduced million deferred income taxes increased million total assets total liabilities previously reported december reduced million company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions none individually significant valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively income taxes paid reflects approximately billion taxes paid divestiture mcc tax benefits relating stock option exercises million million million table contents reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease billion next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures however one item currently discussion internal revenue service irs relating examination company concluded position sustained upon audit however item result unfavorable outcome settlement could material adverse impact companys financial position liquidity results operations interest penalties associated uncertain tax positions amounted expense million million benefit million amounts reflect beneficial impacts various tax settlements including discussed liabilities accrued interest penalties million million december respectively irs currently conducting examinations companys tax returns years well although irss examination companys federal tax returns concluded prior one issue relating refund claim remained open issue resolved company received refund approximately million exceeded receivable previously recorded company resulting tax benefit million addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period irs finalized examination scheringploughs tax years companys unrecognized tax benefits years examination exceeded adjustments related examination period therefore company recorded net million tax provision benefit company recorded outofperiod net tax benefit million related open issue originally raised irs examination issue settled fourth quarter final resolution relating interest owed reached first quarter companys unrecognized tax benefits related issue exceeded settlement amount management concluded exclusion benefit material prior year financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability addition company subsidiaries operating puerto rico singapore tax incentive grants begin expire table contents earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december table contents segment reporting companys operations principally managed products basis comprised four operating segments pharmaceutical animal health alliances healthcare services animal health alliances healthcare services segments material separate reporting included table pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers mercks alliances segment primarily includes results companys relationship astrazeneca lp termination relationship june companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients october company divested consumer care segment see note developed manufactured marketed overthecounter foot care sun care products accounting policies segments described described note table contents sales companys products follows years ended december primary care womens health cardiovascular zetia vytorin diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon dulera follistim aq hospital specialty hepatitis pegintron hiv isentress hospital acute care cubicin cancidas invanz noxafil bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex clarinex cozaarhyzaar arcoxia fosamax zocor propecia vaccines gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales cubicin represent sales subsequent cubist acquisition date sales cubicin reflect sales japan pursuant previously existing licensing agreement amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates included income expense net amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health alliances healthcare services well consumer care divestiture october see note alliances segment includes revenue companys relationship azlp termination june see note revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales revenues also include million received merck connection sale us marketing rights saphris see note revenues reflect million revenue license pipeline compound table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa asia pacific japan latin america reconciliation total segment profits consolidated income taxes follows years ended december segment profits pharmaceutical segment segments total segment profits profits unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs gain sale certain migraine clinical development programs gain divestiture certain ophthalmic products foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt unallocated net segment profits comprised segment sales less standard costs certain operating expenses directly incurred segments internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill product intangible asset impairment charges gains losses sales businesses miscellaneous income expense items table contents equity income affiliates depreciation amortization included segment profits follows pharmaceutical total year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific latin america japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income comprehensive income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included management 's report item responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions discussed note consolidated financial statements company changed manner classifies deferred taxes due adoption accounting standards update balance sheet classification deferred taxes companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production marketing administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production marketing administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders amounts reflect net charge related settlement vioxx shareholder class action litigation see note foreign exchange losses related venezuela see note gain sale companys remaining ophthalmics business international markets see note amounts reflect divestiture mercks consumer care business october see note including billion gain sale amounts also include loss extinguishment debt see note amounts include gain sale certain migraine clinical development programs see note amounts include gains sales businesses see note additional year expense health care reform fee amounts include foreign exchange losses related devaluation companys net monetary assets venezuela see note amounts include gain astrazenecas option exercise see note amounts include tax benefit relating sale sirna therapeutics inc see note amounts reflect acquisition divestiturerelated costs see note impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training includes financial stewardship training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december table contents inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior printed copy sent without charge shareholder requests writing chief ethics compliance officer merck co inc galloping hill road kenilworth nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item